Filed Pursuant to Rule
424(b)(5)
Registration No. 333-223750
PROSPECTUS SUPPLEMENT
(To Prospectus dated June 8, 2018)
Up to $58,500,000
Shares
of Common Stock
We previously entered
into an Open Market Sale AgreementSM, or the Sale Agreement, with Jefferies LLC, or Jefferies, relating to shares of
our common stock, par value $0.001 per share, offered by this prospectus supplement. In accordance with the terms of the Sale Agreement,
as amended, we may offer and sell shares of our common stock having an aggregate offering price of up to $85,000,000, from time
to time through Jefferies, acting as sales agent. As of the date of this prospectus supplement, we have remaining capacity to sell
up to approximately $58,500,000 of our common stock under the amended Sale Agreement.
Sales of the shares of
common stock, if any, under this prospectus supplement will be made by any method permitted that is deemed an “at the market
offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Jefferies
is not required to sell any specific amount, but will act as our sales agent using commercially reasonable efforts consistent with
its normal trading and sales practices. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
Jefferies will be entitled
to compensation at a commission rate of 3% of the gross sales price of the shares sold under the Sale Agreement. See “Plan
of Distribution” beginning on page S-10 for additional information regarding the compensation to be paid to Jefferies. In
connection with the sale of shares of common stock on our behalf, Jefferies will be deemed to be an “underwriter”
within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts.
We have also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities, including civil
liabilities under the Securities Act.
Our common stock trades
on the Nasdaq Global Market under the symbol “SESN”. On October 29, 2020, the last reported sale price of our common
stock on the Nasdaq Global Market was $1.08 per share.
__________________________________________
Investing in our
common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading
“Risk Factors” beginning on page S-6 of this prospectus supplement, page 5 of the accompanying base prospectus, and
under similar headings in the documents incorporated by reference into this prospectus supplement and the accompanying base prospectus.
__________________________________________
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this
prospectus supplement and the accompanying base prospectus is truthful or complete. Any representation to the contrary is a criminal
offense.
Jefferies
The date of this prospectus
supplement is October 30, 2020
TABLE OF CONTENTS
PROSPECTUS SUPPLEMENT
Page
PROSPECTUS
ABOUT
THIS PROSPECTUS SUPPLEMENT
This document is in two
parts. The first part is this prospectus supplement, which describes the terms of this offering of our common stock and also adds
to and updates information contained in the accompanying base prospectus and the documents incorporated by reference into this
prospectus supplement and the accompanying base prospectus. The second part, the accompanying base prospectus, dated June 8, 2018,
including the documents incorporated by reference into it, provides more general information, some of which may not apply to the
shares of common stock offered by this prospectus supplement. Generally, when we refer to this “prospectus”, we are
referring to both parts of this document combined.
To the extent there is
a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the
accompanying base prospectus or in any document incorporated by reference that was filed with the Securities and Exchange Commission,
or SEC, before the date of this prospectus supplement, on the other hand, or the information contained in any free writing prospectus
prepared by or on behalf that we have authorized for use in connection with this offering, you should rely on the information in
this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having
a later date — for example, a document incorporated by reference in this prospectus supplement or the accompanying base prospectus
— the statement in the document having the later date modifies or supersedes the earlier statement unless otherwise specified.
We further note that the
representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated
by reference into this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases,
for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a representation, warranty
or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.
You should rely only on
the information contained in or incorporated by reference into this prospectus and any free writing prospectus prepared by or on
our behalf that we have authorized for use in connection with this offering. We have not, and Jefferies has not, authorized any
dealer, salesperson or other person to provide any information or to make any representation other than those contained or incorporated
by reference into this prospectus or into any free writing prospectus prepared by or on our behalf or to which we have referred
you. If anyone provides you with additional, different or inconsistent information, you should not rely on it. We and Jefferies
take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
We are not, and Jefferies is not, making an offer to sell our common stock in any jurisdiction where the offer or sale is not permitted.
You should assume that the information appearing or incorporated by reference into this prospectus and in any free writing prospectus
prepared by or on our behalf that we have authorized for use in connection with this offering is accurate only as of the date of
each such respective document. Our business, financial condition, results of operations and prospects may have changed since those
dates. You should read this prospectus, including the documents incorporated by reference, and any free writing prospectus prepared
by or on our behalf that we have authorized for use in connection with this offering, in their entirety before making an investment
decision. You should also read and consider the information in the documents we have referred you to in the sections of this prospectus
supplement entitled, “Documents Incorporated By Reference” and “Where You Can Find More Information” and
the sections of the accompanying base prospectus entitled “Incorporation By Reference” and “Where You Can Find
Additional Information”
Other than in the United
States, no action has been taken by us or Jefferies that would permit a public offering of the common stock offered by this prospectus
in any jurisdiction where action for that purpose is required. The common stock offered by this prospectus may not be offered or
sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer
and sale of the shares be distributed or published in any jurisdiction, except under circumstances that will result in compliance
with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised
to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. This
prospectus does not constitute an offer to sell or a solicitation of an offer to buy the common stock offered by this prospectus
in any jurisdiction in which such an offer or a solicitation is unlawful.
Unless stated otherwise
or the context otherwise requires, references in this prospectus to “Sesen,” the “Company,” “we,”
“us,” or “our” refer to Sesen Bio, Inc. and our wholly-owned subsidiaries through which we conduct our
business. Sesen Bio and the Viventia and Sesen logos are our trademarks. We may indicate U.S. trademark registrations and U.S.
trademarks with the symbol “™”. Other third-party logos and product/trade names are registered trademarks or
trade names of their respective owners.
FORWARD-LOOKING
STATEMENTS
This prospectus supplement
and the accompanying base prospectus contain “forward-looking statements” or “forward-looking information”
within the meaning of applicable securities laws (we collectively refer to these items as “forward-looking statements”).
Forward-looking statements are generally identifiable by use of the words “believes,” “may,” “plans,”
“will,” “anticipates,” “intends,” “budgets,” “could,” “estimates,”
“expects,” “forecasts,” “projects” and similar expressions that are not based on historical
fact or that are predictions of or indicate future events and trends, and the negative of such expressions. Forward-looking statements
in this prospectus supplement and the accompanying base prospectus, including the documents incorporated by reference, include
statements about, among other things:
|
•
|
|
our plans and ability to commercialize VicineumTM for the treatment of high-risk, non-muscle invasive bladder cancer, or NMIBC, if approved;
|
|
|
|
|
|
•
|
|
the potential impact of the COVID-19 pandemic on our business;
|
|
|
|
|
|
•
|
|
our expected future loss and accumulated deficit levels;
|
|
|
|
|
|
•
|
|
the difficulties and expenses
associated with obtaining and maintaining regulatory approval of Vicineum for the treatment of high-risk NMIBC in the United States,
the European Union and other jurisdictions, and the labeling under any approval we may obtain;
|
|
•
|
|
our projected financial position and estimated cash burn rate;
|
|
|
|
|
|
•
|
|
our estimates regarding expenses, future revenues, capital requirements and needs for, and ability to obtain, additional financing;
|
|
|
|
|
|
•
|
|
our ability to continue as a going concern;
|
|
|
|
|
|
•
|
|
our need to raise substantial additional capital to fund our operations;
|
|
|
|
|
|
•
|
|
the potential impairment of our goodwill and indefinite lived intangible assets;
|
|
|
|
|
|
•
|
|
the success, cost and timing of our pre-clinical studies and clinical trials in the United States, European Union, Canada and in other foreign jurisdictions;
|
|
|
|
|
|
•
|
|
the potential that results of pre-clinical studies and clinical trials indicate our product candidates are unsafe or ineffective;
|
|
|
|
|
|
•
|
|
our dependence on third parties, including contract research organizations in the conduct of our pre-clinical studies and clinical trials;
|
|
|
|
|
|
•
|
|
our ability to achieve certain future regulatory, development and commercialization milestones under our license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.;
|
|
|
|
|
|
•
|
|
the timing and costs associated with our manufacturing process and technology transfer to FUJIFILM Diosynth Biotechnologies U.S.A., Inc., or Fujifilm, for the production of Vicineum drug substance, and our reliance on Fujifilm to perform under our agreement;
|
|
•
|
|
the timing and costs associated with our manufacturing process and technology transfer to Baxter Oncology GmbH, or Baxter, for the production of Vicineum drug product, and our reliance on Baxter to perform under our agreement;
|
|
•
|
|
market acceptance of our product candidates, the size and growth of the potential markets for our product candidates, and our ability to serve those markets;
|
|
|
|
|
|
•
|
|
obtaining and maintaining
intellectual property protection for our product candidates and our proprietary technology;
the successful development
of our commercialization capabilities, including sales and marketing capabilities;
|
|
|
|
|
|
•
|
|
our expectation to finalize our Biologics License Application, or BLA, submission for Vicineum to the United States Food and Drug Administration, or FDA, by the end of 2020;
|
|
|
|
|
|
•
|
|
our expectation for the potential commercial launch of Vicineum in the U.S., if approved, in mid-2021;
|
|
|
|
|
|
•
|
|
our expectation to file a marketing authorization application for Vicineum with the European Medicines Agency, or EMA, for the treatment of high-risk NMIBC in early 2021, with potential approval in early 2022;
|
|
|
|
|
|
•
|
|
our expectations regarding the amount and timing of milestone and royalty payments pursuant to our exclusive license agreement with Qilu Pharmaceutical Co., Ltd. for the development, manufacture and commercialization of Vicineum in Greater China;
|
|
|
|
|
|
•
|
|
the success of competing therapies and products that are or become available; and
|
|
|
|
|
|
•
|
|
our use of proceeds from this offering.
|
We may not actually achieve
the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed
in the forward-looking statements we make. We have included important factors in the cautionary statements included in this prospectus
supplement and the accompanying base prospectus under the heading “Risk Factors”, and in the documents incorporated
by reference into this prospectus supplement and the accompanying base prospectus, that we believe could cause actual results or
events to differ materially from the forward-looking statements that we make.
Moreover, we operate in
a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for us to predict
all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors,
may cause actual results to differ materially and adversely from those contained in any forward-looking statements we may make.
In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may
not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances
reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility
for the accuracy and completeness of the forward-looking statements. Except as required by law, we undertake no obligation to update
publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual
results or to changes in our expectations.
You should read this prospectus
and the documents incorporated by reference in this prospectus with the understanding that our actual future results, levels of
activity, performance and events and circumstances may be materially different from what we expect. We qualify all forward-looking
statements by these cautionary statements.
SUMMARY
This summary highlights
certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into
this prospectus. This summary is not complete and does not contain all of the information that you should consider in making your
investment decision. For a more complete understanding of our company and this offering, you should read carefully this entire
prospectus, including the information incorporated by reference into this prospectus, and any free writing prospectus prepared
by or on our behalf that we have authorized for use in connection with this offering, including the “Risk Factors”
section beginning on page S-6 of this prospectus supplement, page 5 of the accompanying base prospectus, our consolidated financial
statements and the related notes thereto and the other documents incorporated by reference into this prospectus.
Overview
We are a late-stage clinical
company advancing targeted fusion protein therapeutics, or TFPTs, for the treatment of patients with cancer. We genetically fuse
the targeting antibody fragment and the cytotoxic protein payload into a single molecule which is produced through our proprietary
one-step, microbial manufacturing process. We target tumor cell surface antigens with limited expression on normal cells. Binding
of the target antigen by the TFPT allows for rapid internalization into the targeted cancer cell. We have designed our targeted
proteins to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates where a payload
is chemically attached to a targeting antibody.
Our most advanced product
candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell
adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of
high-risk NMIBC. On December 6, 2019, we initiated our BLA submission for Vicineum to the FDA under Rolling Review. "Rolling
Review" of the BLA enables individual modules to be submitted and reviewed on an ongoing basis, rather than waiting for all
sections to be completed before submission. The submission consisted of Modules 1, 2, 4 and 5, with information amendments to be
submitted to these modules throughout 2020. We anticipate completing Module 3 (Chemistry, Manufacturing and Controls, or CMC) to
finalize the BLA submission by the end of 2020. We may experience disruptions as a result of the COVID-19 pandemic that may impact
our expected timeline to finalize the BLA submission, including manufacturing activities of our contract manufacturers due to limitations
on work and travel imposed or recommended by federal or state governments, employers and others.
Liquidity Position
As of September 30,
2020, we had cash and cash equivalents of approximately $42.0 million. This amount of cash and cash equivalents is preliminary,
subject to adjustment and based solely upon information available to us as of the date of this prospectus supplement. This amount
of cash and cash equivalents is not a comprehensive statement of our results of operations, liquidity or financial condition as
of September 30, 2020, including with respect to our liabilities as of September 30, 2020, and has not been audited or reviewed
by our independent registered public accounting firm. Accordingly, undue reliance should not be placed on this information, and
it should be viewed in the context of all other available information regarding our results of operations, liquidity and financial
condition.
Corporate Information
We were incorporated under
the laws of the state of Delaware on February 25, 2008 under the name NewCo LS14, Inc. We subsequently changed our name to
DeNovo Therapeutics, Inc. in September 2008, to Eleven Biotherapeutics, Inc. in February 2010 and to Sesen Bio, Inc. in May 2018.
Our principal executive offices are located at 245 First Street, Suite 1800, Cambridge, Massachusetts 02142, and our telephone
number is (617) 444-8550. Our website address is www.sesenbio.com. The information contained on, or that can be accessed through,
our website is not a part of this prospectus supplement. We have included our website address in this prospectus supplement solely
as an inactive textual reference.
THE OFFERING
Common
stock offered by us:
|
Shares
having an aggregate offering price of up to $58,500,000.
|
|
|
Common
stock to be outstanding following the offering:
|
Up to 170,794,319
shares (as more fully described below in Outstanding Shares), assuming sales of 54,166,666 shares of our common stock in
this offering at an offering price of $1.08 per share, which was the last reported sale price of our shares on the Nasdaq
Global Market on October 29, 2020. The actual number of shares issued will vary depending on the sales price under this offering.
|
|
|
Manner
of offering:
|
“At the market
offering” that may be made from time to time on the Nasdaq Global Market or other existing trading markets for our common
stock through our sales agent, Jefferies. See “Plan of Distribution” on page S-10 of this prospectus
supplement.
|
|
|
Use
of proceeds:
|
We intend to use
the net proceeds from this offering for CMC and regulatory activities in support of obtaining FDA approval for Vicineum in
the United States for the treatment of high-risk NMIBC, regulatory activities in support of obtaining EMA approval for Vicineum
in the European Union for the treatment of high-risk NMIBC, the preparation for and the commercialization of Vicineum in the
United States for the treatment of high-risk NMIBC, if approved, and general corporate purposes, which may include capital
expenditures and other operating expenses. See “Use of Proceeds.”
|
|
|
Risk factors:
|
Investing in our
common stock involves a high degree of risk. Please read the information contained in and incorporated by reference under the
heading “Risk Factors” beginning on page S-6 of this prospectus supplement, the “Risk Factors” section
beginning on page 5 of the accompanying base prospectus and the documents incorporated by referenced into this prospectus.
|
|
|
Nasdaq Global Market symbol:
|
“SESN”
|
|
|
Outstanding Shares
|
The number of shares
of our common stock to be outstanding after this offering is based on 116,627,653 shares of our common stock outstanding as of
June 30, 2020, and excludes:
• 9,990,484 shares of our common stock issuable upon the exercise of stock options outstanding
as of June 30, 2020 at a weighted-average exercise price of $1.27 per share;
• 2,484,704 shares of our common stock issuable upon the exercise of common stock warrants
outstanding as of June 30, 2020 at a weighted-average exercise price of $0.79 per share;
• 5,084,422 shares of our common stock available for future issuance under our 2014 Stock
Incentive Plan, or 2014 Plan, as of June 30, 2020;
• 25,401
shares of our common stock available for future issuance under our 2014 Employee Stock Purchase Plan, or 2014 ESPP, as
of June 30, 2020; and
•
12,321,022 shares of our common stock issued under the Sale Agreement between July 1, 2020 and October 29, 2020 at a
weighted average sale price of $1.25 per share.
|
RISK
FACTORS
Investing in our common
stock is speculative and involves a high degree of risk. Before making an investment decision, you should carefully consider the
risks described in this prospectus and the documents incorporated by reference into this prospectus, including the “Risk
Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2019, which is incorporated by reference
into this prospectus, as updated by annual, quarterly and other reports and documents we file with the SEC after the date of this
prospectus supplement and that are incorporated by reference into this prospectus. If any of these risks actually occurs, our business,
financial condition or results of operations could be materially adversely affected. These risks and uncertainties are not the
only ones faced by us. Additional risks and uncertainties, including those of which we are currently unaware or that are currently
deemed immaterial, may also materially and adversely affect our business, financial condition, cash flows, prospects and the price
of our common stock.
Risks Related to This
Offering
A substantial number
of shares of our common stock may be sold in the market following this offering, which may depress the market price for our common
stock.
Sales of a substantial
number of shares of our common stock in the public market following this offering could cause the market price of our common stock
to decline. Although there can be no assurance that any of the $58.5 million worth of shares being offered under this prospectus
supplement will be sold or the price at which any such shares might be sold, assuming that an aggregate of 54,166,666 shares
of our common stock are sold pursuant to this prospectus supplement, in each case, for example, at a price of $1.08 per share,
the last reported sale price of our common stock on the Nasdaq Global Market on October 29, 2020, upon completion of this offering,
based on 116,627,653 shares outstanding as of June 30, 2020, we will have outstanding an aggregate of 170,794,319 shares of
common stock, assuming no exercise of outstanding stock options or warrants. A substantial majority of our outstanding shares
are, and all of the shares sold in this offering upon issuance will be, freely tradable without restriction or further registration
under the Securities Act, unless these shares are owned or purchased by “affiliates” as that term is defined in Rule 144
under the Securities Act.
In addition, as of June
30, 2020, there were outstanding (i) options to purchase an aggregate of 9,990,484 shares of our common stock at a weighted average
exercise price of $1.27 per share, of which options to purchase 2,865,623 shares of our common stock were then exercisable and
(ii) warrants to purchase 2,484,704 shares of our common stock at a weighted average exercise price of $0.79 per share. If
these securities are exercised, you may incur further dilution.
Moreover, if we issue
options or warrants to purchase or acquire our common stock in the future and those options or warrants are exercised you may experience
further dilution. Holders of shares of our common stock have no preemptive rights that entitle them to purchase their pro rata
share of any offering of shares of any class or series.
You may experience
future dilution as a result of future equity offerings.
In order to raise additional
capital, we may in the future offer additional shares of common stock or other securities convertible into or exchangeable for
our common stock at prices that may not be the same as the price per share in this offering. We may sell shares of common stock
or other securities convertible into or exchangeable for our shares in any other offering at a price per share that is less than
the price per share paid by investors in this offering, and investors purchasing common stock or other securities convertible into
or exchangeable for our common stock in the future could have rights superior to existing shareholders. The price per share at
which we sell additional shares of common stock or other securities convertible or exchangeable into common stock, in future transactions
may be higher or lower than the price per share paid by investors in this offering.
We have broad discretion
in how we use the net proceeds of this offering, and we may not use these proceeds effectively or in ways with which you agree.
Our management will have
broad discretion as to the use of the net proceeds from this offering. Because of the number and variability of factors that will
determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you
will not have the opportunity, as part of your investment decision, to assess whether the proceeds will be used appropriately.
These net proceeds could be applied in ways that do not improve our operating results or increase the value of your investment.
See “Use of Proceeds” on page S-8 of this
prospectus supplement for a description of our proposed use of proceeds from this offering.
Investors in this
offering will experience immediate dilution in the book value per share of the common stock purchased in the offering.
The common stock
sold in this offering, if any, will be sold from time to time at various prices. However, the expected offering price of our
common stock will be substantially higher than the net tangible book deficit per share of our outstanding common stock. After
giving effect to the sale of shares of our common stock in the aggregate amount of $58.5 million at an assumed offering price
of $1.08 per share, the last reported sale price of our common stock on October 29, 2020 on the Nasdaq Global Market, and
after deducting estimated commissions and estimated offering expenses, our as-adjusted net tangible book deficit as of June
30, 2020 would have been approximately $5.3 million, or approximately $0.03 per share. This represents an immediate decrease
in net tangible book deficit of approximately $0.50 per share to our existing shareholders and immediate dilution of
approximately $1.11 per share to investors participating in this offering. See “Dilution” on page S-9 of this
prospectus supplement.
The actual number
of shares we will issue under the Sale Agreement with Jefferies, at any one time or in total, is uncertain.
Subject to certain limitations
in the Sale Agreement with Jefferies and compliance with applicable law, we have the discretion to deliver placement notices to
Jefferies at any time throughout the term of the Sale Agreement. The number of shares that are sold by Jefferies after delivering
a placement notice will fluctuate based on the market price of the common stock during the sales period and limits we set with
Jefferies.
We have a limited
number of shares of common stock available for future issuance, which may limit our ability to sell under the Sale Agreement unless
we obtain stockholder approval to amend our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares
of common stock.
We
have 200,000,000 authorized shares of common stock under our Restated Certificate of Incorporation, as amended. As of October
29, 2020, we had 128,974,076 shares of common stock outstanding, 10,227,484 shares of common stock issuable upon the exercise
of outstanding stock options, 2,484,704 shares of common stock issuable upon the exercise of outstanding warrants, 4,794,922
shares of common stock reserved for future issuance under the 2014 Plan and 0 shares reserved for future issuance under the
2014 ESPP. As a result, as of October 29, 2020, we had approximately 53.5 million authorized shares of common stock
available for issuance. Due to the limited number of authorized shares available for issuance, we may not
able to offer and sell all of the remaining unsold amount under the Sale Agreement and this prospectus supplement unless we
increase the number of shares we are authorized to issue. This may cause a delay in our future capital raising,
collaboration, partnership or other strategic transactions, and may have a material adverse effect on our business and
financial condition.
We do not expect to
pay dividends in the foreseeable future. As a result, you must rely on stock appreciation for any return on your investment.
We have never paid and
do not anticipate paying cash dividends on shares of our common stock in the foreseeable future. Any payment of cash dividends
will also depend on our financial condition, results of operations, capital requirements and other factors and will be at the discretion
of our board of directors. Accordingly, you will have to rely on capital appreciation, if any, to earn a return on your investment
in our common stock. Furthermore, we may in the future become subject to additional contractual restrictions on, or prohibitions
against, the payment of dividends.
USE
OF PROCEEDS
We may issue and
sell our shares of common stock having aggregate sales proceeds of up to $58.5 million from time to time under this prospectus supplement. Because there is
no minimum offering amount required as a condition to close this offering, the actual total public offering amount,
commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that, in the future, we
will sell any shares under or fully utilize the Sale Agreement with Jefferies as a source of financing.
We currently intend to
use the net proceeds from this offering for preparation for CMC and regulatory activities in support of obtaining FDA approval
of Vicinuem in the United States for the treatment of high-risk NMIBC, regulatory activities in support of obtaining EMA approval
for Vicineum in the European Union for the treatment of high-risk NMIBC, the commercialization of Vicineum in the United States
for the treatment of high-risk NMIBC, if approved, and general corporate purposes, which may include capital expenditures and other
operating expenses.
The precise amount and
timing of the application of these net proceeds will depend upon a number of factors, such as the timing and progress of our research
and development efforts and the timing and progress of any partnering efforts. As of the date of this prospectus supplement, we
cannot specify with certainty all of the particular uses for the net proceeds from this offering. Depending on the outcome of our
efforts and other unforeseen events, our plans and priorities may change and we may apply the net proceeds of this offering in
different manners than we currently anticipate. Accordingly, our management will have broad discretion in the timing and application
of these net proceeds.
DILUTION
If you invest in our
securities in this offering, you will experience immediate dilution to the extent of the difference between the price per share
of our common stock in this offering and the net tangible book deficit per share of our common stock immediately after this offering.
As of June 30, 2020, our historical net tangible book deficit was $62.1 million, or $0.53 per share of our common stock. Our historical
net tangible book deficit per share represents our total tangible assets less total liabilities, divided by the number of shares
of our common stock outstanding as of June 30, 2020.
After giving effect to
the assumed sale of our shares of common stock in the aggregate amount of $58.5 million at an assumed offering price of $1.08
per share, the last reported sale price of our common stock on October 29, 2020 on the Nasdaq Global Market, and after deducting
the underwriting discounts and commissions and estimated offering expenses payable by us, our as-adjusted net tangible book deficit
as of June 30, 2020 would have been approximately $5.3 million, or approximately $0.03 per share of our common stock. This amount
represents an immediate decrease in net tangible book deficit of $0.50 per share to our existing stockholders and immediate
dilution of $1.11 per share of our common stock to purchasers in this offering. The following table illustrates this calculation
on a per share basis:
Assumed
public offering price per share of common stock
|
|
|
|
|
|
$
|
1.08
|
|
Historical
net tangible book deficit per share as of June 30, 2020
|
|
$
|
0.53
|
|
|
|
|
|
Decrease
in net tangible book deficit per share of common stock attributable to investors purchasing our common stock in this offering
|
|
$
|
(0.50
|
)
|
|
|
|
|
As-adjusted
net tangible book deficit per share of common stock immediately after giving effect to this offering
|
|
|
|
|
|
$
|
0.03
|
|
Dilution
per share of common stock to investors purchasing shares of our common stock in this offering
|
|
|
|
|
|
$
|
1.11
|
|
The number of shares
of our common stock to be outstanding after this offering is based on 116,627,653 shares of our common stock outstanding as of
June 30, 2020, and excludes:
|
•
|
9,990,484 shares of our common
stock issuable upon the exercise of stock options outstanding as of June 30, 2020 at
a weighted-average exercise price of $1.27 per share;
|
|
•
|
2,484,704 shares of our common
stock issuable upon the exercise of common stock warrants outstanding as of June 30,
2020 at a weighted-average exercise price of $0.79 per share;
|
|
•
|
5,084,422 shares of our common
stock available for future issuance under our 2014 Plan as of June 30, 2020;
|
|
•
|
25,401 shares of our common
stock available for future issuance under our 2014 ESPP as of June 30, 2020; and
|
|
•
|
12,321,022 shares of our common
stock issued under the Sale Agreement between July 1, 2020 and October 29, 2020 at a
weighted average sale price of $1.25 per share.
|
To the extent that any
of our outstanding warrants or options are exercised, new options are issued under the 2014 Plan or pursuant to inducement awards,
or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this
offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even
if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through
the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.
PLAN
OF DISTRIBUTION
We have entered into
a Sale Agreement, as amended, with Jefferies, under which we may offer and sell up to $85.0 million of our shares of common
stock from time to time through Jefferies acting as agent. Sales of our shares of common stock, if any, under this prospectus
supplement and the accompanying prospectus will be made by any method that is deemed to be an “at the market
offering” as defined in Rule 415(a)(4) under the Securities Act.
Each time we wish to issue
and sell our shares of common stock under the Sale Agreement, we will notify Jefferies of the number of shares to be issued, the
dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any
minimum price below which sales may not be made. Once we have so instructed Jefferies, unless Jefferies declines to accept the
terms of such notice, Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sales
practices to sell such shares up to the amount specified on such terms. The obligations of Jefferies under the Sale Agreement to
sell our shares of common stock are subject to a number of conditions that we must meet.
The settlement of sales
of shares between us and Jefferies is generally anticipated to occur on the second trading day following the date on which the
sale was made. Sales of our shares of common stock as contemplated in this prospectus supplement will be settled through the facilities
of The Depository Trust Company or by such other means as we and Jefferies may agree upon. There is no arrangement for funds to
be received in an escrow, trust or similar arrangement.
We will pay Jefferies
a commission equal to 3% of the aggregate gross proceeds we receive from each sale of our shares of common stock. Because there
is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions
and proceeds to us, if any, are not determinable at this time. In addition, we have agreed in the Sale Agreement to reimburse Jefferies
for the fees and disbursements of its counsel in an amount not to exceed $50,000, in addition to an amount up to $15,000 each quarter
in connection with certain due diligence obligations under the Sale Agreement. We estimate that the total expenses for the offering,
excluding any commissions or expense reimbursement payable to Jefferies under the terms of the Sale Agreement, will be approximately
$150,000. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale
of such shares.
Jefferies will provide
written confirmation to us before the open on The Nasdaq Global Market on the day following each day on which our shares of common
stock are sold under the Sale Agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross
proceeds of such sales and the proceeds to us.
In connection with the
sale of our shares of common stock on our behalf, Jefferies will be deemed to be an “underwriter” within the meaning
of the Securities Act, and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have agreed
to indemnify Jefferies against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to
contribute to payments Jefferies may be required to make in respect of such liabilities.
The offering of our shares
of common stock pursuant to the Sale Agreement will terminate upon the earlier of (i) the sale of all shares of common stock subject
to the Sale Agreement and (ii) the termination of the Sale Agreement as permitted therein. We and Jefferies may each terminate
the Sale Agreement at any time upon ten days’ prior notice.
This summary of the material
provisions of the Sale Agreement does not purport to be a complete statement of its terms and conditions. A copy of the Sale Agreement
is filed as an exhibit to a current report on Form 8-K filed under the Securities Exchange Act of 1934, as amended, or the Exchange
Act, and incorporated by reference in this prospectus supplement.
Jefferies and its affiliates
may in the future provide various investment banking, commercial banking, financial advisory and other financial services for us
and our affiliates, for which services they may in the future receive customary fees. In the course of its business, Jefferies
may actively trade our securities for its own account or for the accounts of customers, and, accordingly, Jefferies may at any
time hold long or short positions in such securities.
A prospectus supplement
and the accompanying prospectus in electronic format may be made available on a website maintained by Jefferies, and Jefferies
may distribute the prospectus supplement and the accompanying prospectus electronically.
LEGAL
MATTERS
The validity of the securities
offered hereby is being passed upon for us by Hogan Lovells US LLP. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is acting
as counsel for the sales agent in connection with this offering.
EXPERTS
Ernst & Young LLP, independent registered public accounting
firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019, and the effectiveness of our internal control over financial reporting as of December 31, 2019, as set forth in their
reports, which contain an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability
to continue as a going concern as described in Note 1 to the consolidated financial statements, included therein, which are incorporated
by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference
in reliance on Ernst & Young LLP's reports, given on their authority as experts in accounting and auditing.
DOCUMENTS
INCORPORATED BY REFERENCE
The SEC allows us to
“incorporate by reference” information into this prospectus, which means that we can disclose important information
to you by referring you to another document filed separately with the SEC. The SEC file number for each of the documents incorporated
by reference in this prospectus is 001-36296. The documents incorporated by reference into this prospectus contain important information
that you should read.
The following documents
are incorporated by reference into this document::
|
•
|
our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020,
filed on May 11, 2020 and August 10, 2020, respectively;
|
|
•
|
our Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01
of Form 8-K and exhibits accompanying such reports that relate to such items) filed with the SEC on January 8, 2020, January 10, 2020, February 7, 2020, February 24, 2020 (as amended on February 26, 2020), March 6, 2020, March 16, 2020, April 21, 2020, May 6, 2020, May 7, 2020 (as amended on May 11, 2020), May 11, 2020, June 2, 2020, 2020, June 18, 2020, July 6, 2020, July 31, 2020,
August 3, 2020, August 5, 2020, August 7, 2020, August 24, 2020, September 15, 2020, September 28, 2020, September 30, 2020, October 6, 2020, October 13, 2020, October 19, 2020 and October 26, 2020.
|
We also incorporate
by reference into this prospectus all documents (other than portions of documents that are either described in paragraph (e) of
Item 201 of Regulation S-K or paragraphs (d)(1)-(3) and (e)(5) of Item 407 of Regulation S-K promulgated by the SEC and current
reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that
are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial registration
statement of which this prospectus forms a part but prior to the termination of the offering. These documents include periodic
reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy
statements. Please see “Where You Can Find More Information” for additional information.
Any statement
contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to
be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other
subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the
statement.
You may request, orally
or in writing, a copy of any or all of the documents incorporated herein by reference. These documents will be provided to you
at no cost, by contacting: Sesen Bio, Inc., Attn: General Counsel, 245 First Street, Suite 1800, Cambridge, MA 02142. In addition,
copies of any or all of the documents incorporated herein by reference may be accessed at our website at http://www.sesenbio.com.
The information on such website is not incorporated by reference and is not a part of this prospectus supplement.
WHERE
YOU CAN FIND MORE INFORMATION
We are a reporting company
and file annual, quarterly and current reports, proxy and information statements and other information with the SEC. This prospectus
is part of a registration statement that we have filed with the SEC relating to the common stock to be offered under this prospectus.
This prospectus supplement does not contain all of the information set forth in the registration statement and the exhibits to
the registration statement. For further information with respect to us and the common stock to be offered under this prospectus
supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement.
The SEC maintains an
internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically
with the SEC, where you may read and copy the registration statement, as well as our reports, proxy and information statements
and other information. The address of the SEC’s web site is http://www.sec.gov.
Copies of certain information
filed by us with the SEC are also available on our website at http://www.sesenbio.com. Information contained in or accessible through
our website does not constitute a part of this prospectus and is not incorporated by reference in this prospectus.
PROSPECTUS
$150,000,000
Debt Securities
Common Stock
Preferred Stock
Depository Shares
Warrants
Units
We may offer and sell up to $150,000,000 in the aggregate of
the securities identified above from time to time in one or more offerings. This prospectus provides a general description of the
securities that we may offer. Each time that we offer securities under this prospectus, we will provide the specific terms of the
securities offered, including the public offering price, in a supplement to this prospectus. Any prospectus supplement may add
to, update or change information contained in this prospectus. You should read this prospectus and any applicable prospectus supplement
together with additional information described under the heading “Where You Can Find More Information” before you make
your investment decision.
The securities may be sold by us to or through underwriters
or dealers, directly to purchasers or through agents designated from time to time. For additional information on the methods of
sale, you should refer to the section entitled “Plan of Distribution” in this prospectus and the comparable section
of any applicable prospectus supplement. If any underwriters are involved in the sale of the securities with respect to which this
prospectus is being delivered, the names of such underwriters and any applicable discounts or commissions and over-allotment options
will be set forth in the applicable prospectus supplement. No securities may be sold without delivery of this prospectus and the
applicable prospectus supplement.
Our common stock trades on the Nasdaq Global Market, or Nasdaq,
under the ticker symbol “EBIO.” On May 15, 2018, the last reported sale price per share of our common stock was
$2.65 per share.
INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK.
RISKS ASSOCIATED WITH AN INVESTMENT IN OUR SECURITIES WILL BE DESCRIBED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND CERTAIN OF
OUR FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION INCORPORATED BY REFERENCE INTO THIS PROSPECTUS, AS DESCRIBED UNDER “RISK
FACTORS” ON PAGE 5.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.
The date of this prospectus is June 8,
2018.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is a part of a registration statement that we
filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registration process. Under this shelf
registration process, we may offer to sell any of the securities, or any combination of the securities, described in this prospectus,
in each case in one or more offerings, up to a total dollar amount of $150,000,000.
This prospectus provides you only with a general description
of the securities that we may offer. Each time securities are sold under the shelf registration statement, we will provide a prospectus
supplement or free writing prospectus that will contain specific information about the terms of those securities and the terms
of that offering. The prospectus supplement or free writing prospectus may also add, update or change information contained in
this prospectus. You should read both this prospectus and any prospectus supplement or free writing prospectus, including all documents
incorporated by reference herein and therein, together with the additional information described under “Where You Can Find
More Information” below.
The registration statement that contains this prospectus, including
the exhibits to the registration statement and the information incorporated by reference, contains additional information about
the securities offered under this prospectus. That registration statement can be read at the SEC website or at the SEC offices
mentioned below under the heading “Where You Can Find More Information.” You should read the exhibits carefully for
provisions that may be important to you.
We
have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained
or incorporated by reference in this prospectus and any accompanying prospectus supplement or free writing prospectus. You must
not rely upon any information or representation not contained or incorporated by reference in this prospectus or an accompanying
prospectus supplement or free writing prospectus. This prospectus and the accompanying prospectus supplement or free writing prospectus,
if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities
to which they relate, nor do this prospectus and the accompanying prospectus supplement or free writing prospectus, if any, constitute
an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to
make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and
the accompanying prospectus supplement or free writing prospectus, if any, is accurate on any date subsequent to the date set forth
on the front of such document or that any information we have incorporated by reference is correct on any date subsequent to the
date of the document incorporated by reference, even though this prospectus and any accompanying prospectus supplement or free
writing prospectus is delivered or securities are sold on a later date.
References in this prospectus to the terms “the Company,”
“Eleven,” “we,” “our” and “us” or other similar terms mean Eleven Biotherapeutics, Inc.
and our wholly owned subsidiaries, unless we state otherwise or the context indicates otherwise.
FORWARD-LOOKING STATEMENTS
This prospectus, including the documents that we incorporate
by reference herein, includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.
For this purpose, any statements contained herein, other than statements of historical fact, regarding our strategy, future operations,
future product research or development, future financial position, future revenues, projected costs, prospects, plans and objectives
of management, are forward-looking statements. The words “anticipate,” “believe,” “goals,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue” and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words.
The forward-looking statements in this prospectus include, among
other things, statements about:
|
·
|
our expected future loss and accumulated deficit levels;
|
|
·
|
our projected financial position and estimated cash burn rate;
|
|
·
|
our estimates regarding expenses, future revenues, capital requirements and needs for, and ability to obtain, additional financing;
|
|
·
|
our ability to continue as a going concern;
|
|
·
|
our need to raise substantial additional capital to fund our operations;
|
|
·
|
the potential impairment of our goodwill and indefinite lived intangible assets;
|
|
·
|
the effect of recent changes in our senior management team on our business;
|
|
·
|
the success, cost and timing of our pre-clinical studies and clinical trials in the United States, Canada and in other foreign
jurisdictions;
|
|
·
|
the potential that results of pre-clinical studies and clinical trials indicate our product candidates are unsafe or ineffective;
|
|
·
|
our dependence on third parties, including contract research organizations, or CROs, in the conduct of our pre-clinical studies
and clinical trials;
|
|
·
|
the difficulties and expenses associated with obtaining and maintaining regulatory approval of our product candidates and companion
diagnostics, if any, in the United States, Canada and in other foreign jurisdictions, and the labeling under any approval we may
obtain;
|
|
·
|
our plans and ability to develop and commercialize our product candidates;
|
|
·
|
our ability to achieve certain future regulatory, development and commercialization milestones under our license agreement,
which we refer to as the License Agreement, with F. Hoffmann-La Roche Ltd and Hoffmann La-Roche Inc., or collectively, Roche;
|
|
·
|
market acceptance of our product candidates, the size and growth of the potential markets for our product candidates, and our
ability to serve those markets;
|
|
·
|
obtaining and maintaining intellectual property protection for our product candidates and our proprietary technology;
|
|
·
|
the successful development of our commercialization capabilities, including sales and marketing capabilities; and
|
|
·
|
the success of competing therapies and products that are or become available.
|
Our product candidates are investigational biologics undergoing
clinical development and have not been approved by the U.S. Food and Drug Administration, or FDA, Health Canada, or the European
Commission. Our product candidates have not been, nor may they ever be, approved by any regulatory agency or competent authorities
nor marketed anywhere in the world.
We may not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements, and our stockholders should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements
we make. We have included important factors in the cautionary statements included in this prospectus, particularly in the “Risk
Factors” section beginning on page 5 and those identified under the heading “Risk Factors” in our most recent
annual report on Form 10-K, that could cause actual results or events to differ materially from the forward-looking statements
that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions,
joint ventures or investments we may make.
You should read this prospectus and the documents that we have
filed as exhibits to the registration statement of which this prospectus forms a part completely and with the understanding that
our actual future results may be materially different from what we expect. The forward-looking statements contained in this prospectus
are made as of the date of this prospectus and we do not assume any obligation to update any forward-looking statements, whether
as a result of new information, future events or otherwise, except as required by applicable law.
THE COMPANY
Overview
We are a biologics oncology company focused primarily on designing,
engineering and developing targeted next generation antibody drug conjugates, or ADCs. Our next generation ADCs are single protein
therapeutics composed of targeting moieties genetically fused via a peptide linker domain to cytotoxic protein payloads that are
produced through our proprietary one-step manufacturing process. We target tumor cell surface antigens that allow for rapid internalization
into the targeted cancer cell while having limited expression on normal cells. We have designed our next generation ADCs to overcome
the fundamental efficacy and safety challenges inherent in existing ADCs, where a payload is chemically attached to a targeting
antibody.
Our most advanced product candidate is VB4-845, also known as
Vicinium™ for the treatment of high-grade non-muscle invasive bladder cancer, or NMIBC, which is a locally-administered next
generation ADC. In a completed Phase 2 clinical trial, of the 45 evaluable subjects treated with Vicinium, 40% achieved a complete
response or no evidence of disease at three months while 16% remained disease-free for at least 18 months. In the third quarter
of 2015, we, through our subsidiary Viventia Bio Inc., or Viventia, commenced in the United States and Canada a Phase 3 clinical
trial of Vicinium for the treatment of subjects with high-grade non-muscle invasive bladder cancer, or NMIBC. We completed enrollment
in this clinical trial of the primary endpoint population, subjects with carcinoma in situ, in March 2018 and anticipate reporting
three-month data in May 2018 and twelve-month data in mid-2019. In June 2017, we entered into a Cooperative Research
and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, for the development of Vicinium in combination
with AstraZeneca’s immune checkpoint inhibitor, durvalumab, for the treatment of NMIBC. Under the terms of the CRADA, the
NCI will conduct a Phase 1 clinical trial in subjects with high-grade NMIBC to evaluate the safety, efficacy and biological correlates
of Vicinium in combination with durvalumab. This Phase 1 trial is open and actively recruiting patients.
Vicinium has also been evaluated as a locally-administered next
generation ADC for the treatment of squamous cell carcinoma of the head and neck, or SCCHN. Vicinium, or VB4-845, for the treatment
of SCCHN had been previously designated as Proxinium™ to indicate its different fill volume and vial size for local administration
via intratumoral injection. In our two Phase 1 clinical trials, 53% of evaluable subjects treated with Vicinium demonstrated antitumor
activity with epithelial cell adhesion molecule, or EpCAM-expressing tumors as assessed by the investigators’ clinical measurements,
the investigators’ overall assessment including qualitative changes, and assessment of available radiologic data. In addition,
three out of the four subjects with complete responses of injected tumors had regression or complete resolution of adjacent non
injected lesions. In a Phase 2 clinical trial, we observed tumor shrinkage in 10 of the 14 evaluable subjects (71.4%). We intend
to initiate a Phase 1/2a clinical trial that will explore the potential of Vicinium in combination with a checkpoint inhibitor
for the treatment of SCCHN and are actively seeking partners for a combination program. In addition to our locally-administered
next generation ADCs, our pipeline also includes systemically-administered next generation ADCs in development. Our systemically-administered
next generation ADCs are built around our proprietary de-immunized variant of the plant-derived cytotoxin bouganin, or deBouganin.
Our lead systemically-administered product candidate, VB6-845d, is being developed for the treatment of multiple types of EpCAM-positive
solid tumors. VB6-845d is administered by intravenous infusion. A Phase 1 clinical trial conducted with VB6-845, the prior version
of VB6-845d, revealed no clinically relevant immune response to the deBouganin payload.
We have deferred further development of VB6-845d and of Vicinium
for the treatment of SCCHN in order to focus our efforts and our resources on our ongoing development of Vicinium for the treatment
of high-grade NMIBC. We
are also exploring collaborations for Vicinium for the treatment
of SCCHN and VB6-845d, and plan on submitting an Investigational New Drug application, or IND, with VB6-845d once funding or a
partner is secured for this program.
We maintain global development, marketing and commercialization
rights for all of our next generation ADC-based product candidates. We intend to explore various commercialization strategies to
market our approved products. If we obtain regulatory approval for Vicinium for the treatment of high-grade NMIBC, we may build
a North American specialty urology sales force to market the product or seek commercialization partners. If we obtain regulatory
approval for Vicinium for the treatment of SCCHN or for our other product candidates, including VB6-845d, we may seek partners
with oncology expertise in order to maximize the commercial value of each asset or a portfolio of assets. We also own or exclusively
license worldwide intellectual property rights for all of our next generation ADC-based product candidates, covering our key patents
with protection ranging from 2018 to 2036.
Our locally-administered next generation ADCs contain a targeting
moiety that is designed to bind to EpCAM, which is a protein over expressed in many cancers. This targeting moiety is genetically
fused to a truncated form of ETA, which is an immunogenic cytotoxic protein payload that is produced by the bacterial species,
Pseudomonas. These product candidates are designed to bind to EpCAM on the surface of cancer cells. The next generation ADC-EpCAM
complex is subsequently internalized into the cell and, once inside the cell, the next generation ADC is cleaved by a cellular
enzyme to release the cytotoxic protein payload, thus enabling cancer cell-killing. We believe that our next generation ADCs designed
for local administration may not only directly kill cancer cells through a targeted delivery of a cytotoxic protein payload, but
also potentiate an anti-cancer therapeutic immune response in cancer cells near the site of administration. This immune response
is believed to be triggered by both the immunogenic cell death of the cancer cells due to our payload’s mechanism of action
and the subsequent release of tumor antigens and the immunologically active setting created by the nature of the cytotoxic protein
payloads.
Our early pipeline product candidate, VB6-845d, was being developed
for systemic administration as a treatment for multiple types of EpCAM-positive solid tumors. VB6-845d is a next generation ADC
consisting of an EpCAM targeting Fab genetically linked to deBouganin, a novel plant derived cytotoxic payload that we have optimized
for minimal immunogenic potential.
On June 10, 2016, we entered into a License Agreement,
or the License Agreement, with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., or collectively, Roche, pursuant to which we
licensed our monoclonal antibody EBI-031 and all other IL-6 antagonist antibody technology owned by us. Under the License Agreement,
Roche is required to continue developing EBI-031 at its cost. At the time of the License Agreement, EBI-031, which was derived
using our previous AMP-Rx platform, was in pre-clinical development as an intravitreal injection for diabetic macular edema and
uveitis. We have received $30.0 million in payments from Roche pursuant to the License Agreement, including a $7.5 million upfront
payment and a $22.5 million milestone payment as a result of the IND application for EBI-031 becoming effective. We are also entitled
to receive up to an additional $240.0 million upon the achievement of other specified regulatory, development and commercial milestones,
as well as royalties based on net sales of potential future products containing EBI-031 or any other potential future products
containing other IL-6 compounds.
We also previously invested a significant portion of our efforts
and financial resources in the development of our product candidate isunakinra (EBI-005) for the treatment of subjects with dry
eye disease and allergic conjunctivitis. Based on negative results from our completed Phase 3 clinical trials in dry eye disease
and allergic conjunctivitis, we do not plan to pursue further development of isunakinra.
Corporate Information
We were incorporated under the laws of the state of Delaware
on February 25, 2008 under the name NewCo LS14, Inc. We subsequently changed our name to DeNovo Therapeutics, Inc.
in September 2008 and again to Eleven Biotherapeutics, Inc. in February 2010. Our principal executive offices are
located at 245 First Street, Suite 1800, Cambridge, Massachusetts 02142, and our telephone number is (617) 444-8550.
Our website address is www.elevenbio.com. The information contained on, or that can be accessed through, our website is not a part
of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
Eleven Biotherapeutics, Viventia Bio and the Viventia and Eleven
logos are our trademarks. The other trademarks, trade names and service marks appearing in this prospectus are the property of
their respective owners.
Implications of Being an Emerging Growth Company
We are an “emerging growth company,” as defined
in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earliest
of (1) the last day of the fiscal year following the fifth anniversary of our initial public offering, or December 31,
2019, (2) the last day of the fiscal year after our annual gross revenue is $1.07 billion or more, (3) the date on which
we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities and (4) the
last day of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of the
end of the second quarter of that fiscal year.
For as long as we remain an “emerging growth company,”
we may take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are
not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation
requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and
financial statements in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote to approve executive compensation and shareholder approval of any golden parachute payments not previously approved.
We may take advantage of one or more of these reporting exemptions until we are no longer an “emerging growth company.”
The JOBS Act provides that an “emerging growth company”
can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably
elected not to avail ourselves of this exemption and, therefore, we are subject to the same new or revised accounting standards
as other public companies that are not “emerging growth companies.”
RISK FACTORS
Our business is influenced by many factors that are difficult
to predict, and that involve uncertainties that may materially affect actual operating results, cash flows and financial condition.
Before making an investment decision, you should carefully consider these risks, including those set forth in the “Risk Factors”
section of our most recent Annual Report on Form 10-K filed with the SEC, as revised or supplemented by our Quarterly Reports
on Form 10-Q filed with the SEC since the filing of our most recent Annual Report on Form 10-K, each of which is incorporated
by reference into this prospectus. You should also carefully consider any other information we include or incorporate by reference
in this prospectus or include in any applicable prospectus supplement. Each of the risks described in these sections and documents
could materially and adversely affect our business, financial condition, results of operations and prospects, and could result
in a partial or complete loss of your investment.
USE OF PROCEEDS
Unless otherwise indicated in a prospectus supplement or free
writing prospectus, we anticipate that the net proceeds from our sale of any securities will be used to fund the ongoing clinical
development of Vicinium and for general corporate purposes, which may include capital expenditures and funding our working capital
needs. We expect from time to time to evaluate the acquisition of businesses, products and technologies for which a portion of
the net proceeds may be used, although we currently are not planning or negotiating any such transactions. Pending such uses, we
may invest the net proceeds in investment grade interest-bearing securities.
The amounts actually expended for each purpose may vary significantly
depending upon numerous factors, including the amount and timing of the proceeds from any sale of securities. Expenditures will
also depend upon the establishment of collaborative arrangements with other companies, the availability of additional financing
and other factors. Investors will be relying on the judgment of our management regarding the application of the proceeds of any
sale of securities.
RATIO OF EARNINGS TO FIXED CHARGES
Any time debt securities are offered pursuant to this prospectus,
we will provide a table setting forth our ratio of earnings to fixed charges on a historical basis in the applicable prospectus
supplement, if required.
DESCRIPTION OF OUR DEBT SECURITIES
We may offer debt securities which may be senior or subordinated.
We refer to the senior debt securities and the subordinated debt securities collectively as debt securities. The following description
summarizes the general terms and provisions of the debt securities. We will describe the specific terms of the debt securities
and the extent, if any, to which the general provisions summarized below apply to any series of debt securities in the prospectus
supplement relating to the series and any applicable free writing prospectus that we authorize to be delivered. When we refer to
“the Company,” “we,” “our,” and “us” in this section, we mean Eleven Biotherapeutics, Inc.
excluding, unless the context otherwise requires or as otherwise expressly stated, our subsidiaries.
We may issue senior debt securities from time to time, in one
or more series under a senior indenture to be entered into between us and a senior trustee to be named in a prospectus supplement,
which we refer to as the senior trustee. We may issue subordinated debt securities from time to time, in one or more series under
a subordinated indenture to be entered into between us and a subordinated trustee to be named in a prospectus supplement, which
we refer to as the subordinated trustee. Together, the senior indenture and the subordinated indenture are referred to as the indentures
and, together, the senior trustee and the subordinated trustee are referred to as the trustees. This prospectus briefly outlines
some of the provisions of the indentures. The following summary of the material provisions of the indentures is qualified in its
entirety by the provisions of the indentures, including definitions of certain terms used in the indentures. Wherever we refer
to particular sections or defined terms of the indentures, those sections or defined terms are incorporated by reference in this
prospectus or the applicable prospectus supplement. You should review the indentures that are incorporated by reference to the
registration statement of which this prospectus forms a part for additional information.
None of the indentures will limit the amount of debt securities
that we may issue. The applicable indenture will provide that debt securities may be issued up to an aggregate principal amount
authorized from time to time by us and may be payable in any currency or currency unit designated by us or in amounts determined
by reference to an index.
General
The senior debt securities will constitute our unsecured and
unsubordinated general obligations and will rank pari passu with our other unsecured and unsubordinated obligations. The subordinated
debt securities will constitute our unsecured and subordinated general obligations and will be junior in right of payment to our
senior indebtedness (including senior debt securities), as described under the heading “—Certain Terms of the Subordinated
Debt Securities—Subordination.” The debt securities will be structurally subordinated to all existing and future indebtedness
and other liabilities of our subsidiaries unless such subsidiaries expressly guarantee such debt securities.
The debt securities will be our unsecured obligations. Any secured
debt or other secured obligations will be effectively senior to the debt securities to the extent of the value of the assets securing
such debt or other obligations.
The applicable prospectus supplement and/or free writing prospectus
will include any additional or different terms of the debt securities of any series being offered, including the following terms:
|
·
|
the title and type of the debt securities;
|
|
·
|
whether the debt securities will be senior or subordinated debt securities, and, with respect to debt securities issued under
the subordinated indenture the terms on which they are subordinated;
|
|
·
|
the aggregate principal amount of the debt securities;
|
|
·
|
the price or prices at which we will sell the debt securities;
|
|
·
|
the maturity date or dates of the debt securities and the right, if any, to extend such date or dates;
|
|
·
|
the rate or rates, if any, per year, at which the debt securities will bear interest, or the method of determining such rate
or rates;
|
|
·
|
the date or dates from which such interest will accrue, the interest payment dates on which such interest will be payable or
the manner of determination of such interest payment dates and the related record dates;
|
|
·
|
the right, if any, to extend the interest payment periods and the duration of that extension;
|
|
·
|
the manner of paying principal and interest and the place or places where principal and interest will be payable;
|
|
·
|
provisions for a sinking fund, purchase fund or other analogous fund, if any;
|
|
·
|
any redemption dates, prices, obligations and restrictions on the debt securities;
|
|
·
|
the currency, currencies or currency units in which the debt securities will be denominated and the currency, currencies or
currency units in which principal and interest, if any, on the debt securities may be payable;
|
|
·
|
any conversion or exchange features of the debt securities;
|
|
·
|
whether and upon what terms the debt securities may be defeased;
|
|
·
|
any events of default or covenants in addition to or in lieu of those set forth in the indenture;
|
|
·
|
whether the debt securities will be issued in definitive or global form or in definitive form only upon satisfaction of certain
conditions;
|
|
·
|
whether the debt securities will be guaranteed as to payment or performance;
|
|
·
|
any special tax implications of the debt securities; and
|
|
·
|
any other material terms of the debt securities.
|
When we refer to “principal” in this section with
reference to the debt securities, we are also referring to “premium, if any.”
We may from time to time, without notice to or the consent of
the holders of any series of debt securities, create and issue further debt securities of any such series ranking equally with
the debt securities of such series in all respects (or in all respects other than (1) the payment of interest accruing prior
to the issue date of such further debt securities or (2) the first payment of interest following the issue date of such further
debt securities). Such further debt securities may be consolidated and form a single series with the debt securities of such series
and have the same terms as to status, redemption or otherwise as the debt securities of such series.
You may present debt securities for exchange and you may present
debt securities for transfer in the manner, at the places and subject to the restrictions set forth in the debt securities and
the applicable prospectus supplement. We will provide you those services without charge, although you may have to pay any tax or
other governmental charge payable in connection with any exchange or transfer, as set forth in the indenture.
Debt securities may bear interest at a fixed rate or a floating
rate. Debt securities bearing no interest or interest at a rate that at the time of issuance is below the prevailing market rate
(original issue discount securities) may be sold at a discount below their stated principal amount. U.S. federal income tax considerations
applicable to any such discounted debt securities or to certain debt securities issued at par which are treated as having been
issued at a discount for U.S. federal income tax purposes will be described in the applicable prospectus supplement.
We may issue debt securities with the principal amount payable
on any principal payment date, or the amount of interest payable on any interest payment date, to be determined by reference to
one or more currency exchange rates, securities or baskets of securities, commodity prices or indices. You may receive a payment
of principal on any principal payment date, or a payment of interest on any interest payment date, that is greater than or less
than the amount of principal or interest otherwise payable on such dates, depending on the value on such dates of the applicable
currency, security or basket of securities, commodity or index. Information as to the methods for determining the amount of principal
or interest payable on any date, the currencies, securities or baskets of securities, commodities or indices to which the amount
payable on such date is linked and certain related tax considerations will be set forth in the applicable prospectus supplement.
Certain Terms of the Senior Debt Securities
Covenants.
Unless we indicate otherwise in a prospectus supplement, the senior debt securities will not contain any financial or restrictive
covenants, including covenants restricting either us or any of our subsidiaries from incurring, issuing, assuming or guaranteeing
any indebtedness secured by a lien on any of our or our subsidiaries’ property or capital stock, or restricting either us
or any of our subsidiaries from entering into sale and leaseback transactions.
Consolidation,
Merger and Sale of Assets. Unless we indicate otherwise in a prospectus supplement, we may not consolidate with
or merge into any other person, in a transaction in which we are not the surviving corporation, or convey, transfer or lease our
properties and assets substantially as an entirety to any person, in either case, unless:
|
·
|
the successor entity, if any, is a U.S. corporation, limited liability company, partnership or trust (subject to certain exceptions
provided for in the senior indenture);
|
|
·
|
the successor entity assumes our obligations on the senior debt securities and under the senior indenture;
|
|
·
|
immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing; and
|
|
·
|
certain other conditions are met.
|
No
Protection in the Event of a Change in Control. Unless we indicate otherwise in a prospectus supplement with respect
to a particular series of senior debt securities, the senior debt securities will not contain any provisions that may afford holders
of the senior debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction
(whether or not such transaction results in a change in control).
Events
of Default. Unless we indicate otherwise in a prospectus supplement with respect to a particular series of senior
debt securities, the following are events of default under the senior indenture for any series of senior debt securities:
|
·
|
failure to pay interest on any senior debt securities of such series when due and payable, if that default continues for a
period of 30 days (or such other period as may be specified for such series);
|
|
·
|
failure to pay principal on the senior debt securities of such series when due and payable whether at maturity, upon redemption,
by declaration or otherwise (and, if specified for such series, the continuance of such failure for a specified period);
|
|
·
|
default in the performance of or breach of any of our covenants or agreements in the senior indenture applicable to senior
debt securities of such series, other than a covenant breach which is specifically dealt with elsewhere in the senior indenture,
and that default or breach continues for a period of 90 days after we receive written notice from the trustee or from the holders
of 25% or more in aggregate principal amount of the senior debt securities of such series;
|
|
·
|
certain events of bankruptcy or insolvency, whether or not voluntary; and
|
|
·
|
any other event of default provided for in such series of senior debt securities as may be specified in the applicable prospectus
supplement.
|
The default by us under any other debt, including any other
series of debt securities, is not a default under the senior indenture.
If an event of default other than an event of default specified
in the fourth bullet point above occurs with respect to a series of senior debt securities and is continuing under the senior indenture,
then, and in each such case, either the trustee or the holders of not less than 25% in aggregate principal amount of such series
then outstanding under the senior indenture (each such series voting as a separate class) by written notice to us and to the trustee,
if such notice is given by the holders, may, and the trustee at the request of such holders shall, declare the principal amount
of and
accrued interest on such series of senior debt securities to
be immediately due and payable, and upon this declaration, the same shall become immediately due and payable.
If an event of default specified in the fourth bullet point
above occurs and is continuing, the entire principal amount of and accrued interest on each series of senior debt securities then
outstanding shall become immediately due and payable.
Unless otherwise specified in the prospectus supplement relating
to a series of senior debt securities originally issued at a discount, the amount due upon acceleration shall include only the
original issue price of the senior debt securities, the amount of original issue discount accrued to the date of acceleration and
accrued interest, if any.
Upon certain conditions, declarations of acceleration may be
rescinded and annulled and past defaults may be waived by the holders of a majority in aggregate principal amount of all the senior
debt securities of such series affected by the default, each series voting as a separate class. Furthermore, subject to various
provisions in the senior indenture, the holders of a majority in aggregate principal amount of a series of senior debt securities,
by notice to the trustee, may waive an existing default or event of default with respect to such senior debt securities and its
consequences, except a default in the payment of principal of or interest on such senior debt securities or in respect of a covenant
or provision of the senior indenture which cannot be modified or amended without the consent of the holders of each such senior
debt security. Upon any such waiver, such default shall cease to exist, and any event of default with respect to such senior debt
securities shall be deemed to have been cured, for every purpose of the senior indenture; but no such waiver shall extend to any
subsequent or other default or event of default or impair any right consequent thereto.
The holders of a majority in aggregate principal amount of a
series of senior debt securities may direct the time, method and place of conducting any proceeding for any remedy available to
the trustee or exercising any trust or power conferred on the trustee with respect to such senior debt securities. However, the
trustee may refuse to follow any direction that conflicts with law or the senior indenture, that may involve the trustee in personal
liability or that the trustee determines in good faith may be unduly prejudicial to the rights of holders of such series of senior
debt securities not joining in the giving of such direction and may take any other action it deems proper that is not inconsistent
with any such direction received from holders of such series of senior debt securities. A holder may not pursue any remedy with
respect to the senior indenture or any series of senior debt securities unless:
|
·
|
the holder gives the trustee written notice of a continuing event of default;
|
|
·
|
the holders of at least 25% in aggregate principal amount of such series of senior debt securities make a written request to
the trustee to pursue the remedy in respect of such event of default;
|
|
·
|
the requesting holder or holders offer the trustee indemnity satisfactory to the trustee against any costs, liability or expense;
|
|
·
|
the trustee does not comply with the request within 60 days after receipt of the request and the offer of indemnity; and
|
|
·
|
during such 60-day period, the holders of a majority in aggregate principal amount of such series of senior debt securities
do not give the trustee a direction that is inconsistent with the request.
|
These limitations, however, do not apply to the right of any
holder of a senior debt security to receive payment of the principal of and interest on such senior debt security in accordance
with the terms of such debt security, or to bring
suit for the enforcement of any such payment in accordance with
the terms of such debt security, on or after the due date for the senior debt securities, which right shall not be impaired or
affected without the consent of the holder.
The senior indenture requires certain of our officers to certify,
on or before a fixed date in each year in which any senior debt security is outstanding, as to their knowledge of our compliance
with all covenants, agreements and conditions under the senior indenture.
Satisfaction
and Discharge. We can satisfy and discharge our obligations to holders of any series of debt securities if:
|
·
|
we pay or cause to be paid, as and when due and payable, the principal of and any interest on all senior debt securities of
such series outstanding under the senior indenture; or
|
|
·
|
all senior debt securities of such series have become due and payable or will become due and payable within one year (or are
to be called for redemption within one year) and we deposit in trust a combination of cash and U.S. government or U.S. government
agency obligations that will generate enough cash to make interest, principal and any other payments on the debt securities of
that series on their various due dates.
|
Under current U.S. federal income tax law, the deposit and our
legal release from the debt securities would be treated as though we took back your debt securities and gave you your share of
the cash and debt securities or bonds deposited in trust. In that event, you could recognize gain or loss on the debt securities
you give back to us. Purchasers of the debt securities should consult their own advisers with respect to the tax consequences to
them of such deposit and discharge, including the applicability and effect of tax laws other than the U.S. federal income tax law.
Defeasance.
Unless the applicable prospectus supplement provides otherwise, the following discussion of legal defeasance and discharge and
covenant defeasance will apply to any series of debt securities issued under the indentures.
Legal
Defeasance. We can legally release ourselves from any payment or other obligations on the debt securities of any series
(called “legal defeasance”) if certain conditions are met, including the following:
|
·
|
We deposit in trust for your benefit and the benefit of all other direct holders of the debt securities of the same series
a combination of cash and U.S. government or U.S. government agency obligations that will generate enough cash to make interest,
principal and any other payments on the debt securities of that series on their various due dates.
|
|
·
|
There is a change in current U.S. federal income tax law or an IRS ruling that lets us make the above deposit without causing
you to be taxed on the debt securities any differently than if we did not make the deposit and instead repaid the debt securities
ourselves when due. Under current U.S. federal income tax law, the deposit and our legal release from the debt securities would
be treated as though we took back your debt securities and gave you your share of the cash and debt securities or bonds deposited
in trust. In that event, you could recognize gain or loss on the debt securities you give back to us.
|
|
·
|
We deliver to the trustee a legal opinion of our counsel confirming the tax law change or ruling described above.
|
|
·
|
If we accomplish legal defeasance, as described above, you would have to rely solely on the trust deposit for repayment of
the debt securities. You could not look to us for repayment in the event of any shortfall.
|
Covenant
Defeasance. Without any change of current U.S. federal tax law, we can make the same type of deposit described above
and be released from some of the covenants in the debt securities (called “covenant defeasance”). In that event, you
would lose the protection of those covenants but would gain the protection of having money and securities set aside in trust to
repay the debt securities. In order to achieve covenant defeasance, we must do the following (among other things):
|
·
|
We must deposit in trust for your benefit and the benefit of all other direct holders of the debt securities of the same series
a combination of cash and U.S. government or U.S. government agency obligations that will generate enough cash to make interest,
principal and any other payments on the debt securities of that series on their various due dates.
|
|
·
|
We must deliver to the trustee a legal opinion of our counsel confirming that under current U.S. federal income tax law we
may make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit
and instead repaid the debt securities ourselves when due.
|
If we accomplish covenant defeasance, you could still look to
us for repayment of the debt securities if there were a shortfall in the trust deposit. In fact, if one of the events of default
occurred (such as our bankruptcy) and the debt securities become immediately due and payable, there may be such a shortfall. Depending
on the events causing the default, you may not be able to obtain payment of the shortfall.
Modification
and Waiver. We and the trustee may amend or supplement the senior indenture or the senior debt securities without the
consent of any holder:
|
·
|
to convey, transfer, assign, mortgage or pledge any assets as security for the senior debt securities of one or more series;
|
|
·
|
to evidence the succession of a corporation, limited liability company, partnership or trust to us, and the assumption by such
successor of our covenants, agreements and obligations under the senior indenture or to otherwise comply with the covenant relating
to mergers, consolidations and sales of assets;
|
|
·
|
to comply with requirements of the SEC in order to effect or maintain the qualification of the senior indenture under the Trust
Indenture Act of 1939, as amended, or the Trust Indenture Act;
|
|
·
|
to add to our covenants such new covenants, restrictions, conditions or provisions for the protection of the holders, and to
make the occurrence, or the occurrence and continuance, of a default in any such additional covenants, restrictions, conditions
or provisions an event of default;
|
|
·
|
to cure any ambiguity, defect or inconsistency in the senior indenture or in any supplemental indenture or to conform the senior
indenture or the senior debt securities to the description of senior debt securities of such series set forth in this prospectus
or any applicable prospectus supplement;
|
|
·
|
to provide for or add guarantors with respect to the senior debt securities of any series;
|
|
·
|
to establish the form or forms or terms of the senior debt securities as permitted by the senior indenture;
|
|
·
|
to evidence and provide for the acceptance of appointment under the senior indenture by a successor trustee, or to make such
changes as shall be necessary to provide for or facilitate the administration of the trusts in the senior indenture by more than
one trustee;
|
|
·
|
to add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms, purposes of
issue, authentication and delivery of any series of senior debt securities;
|
|
·
|
to make any change to the senior debt securities of any series so long as no senior debt securities of such series are outstanding;
or
|
|
·
|
to make any change that does not adversely affect the rights of any holder in any material respect.
|
Other amendments and modifications of the senior indenture or
the senior debt securities issued may be made, and our compliance with any provision of the senior indenture with respect to any
series of senior debt securities may be waived, with the consent of the holders of a majority of the aggregate principal amount
of the outstanding senior debt securities of all series affected by the amendment or modification (voting together as a single
class); provided, however, that each affected holder must consent to any modification, amendment or waiver that:
|
·
|
extends the final maturity of any senior debt securities of such series;
|
|
·
|
reduces the principal amount of any senior debt securities of such series;
|
|
·
|
reduces the rate or extends the time of payment of interest on any senior debt securities of such series;
|
|
·
|
reduces the amount payable upon the redemption of any senior debt securities of such series;
|
|
·
|
changes the currency of payment of principal of or interest on any senior debt securities of such series;
|
|
·
|
reduces the principal amount of original issue discount securities payable upon acceleration of maturity or the amount provable
in bankruptcy;
|
|
·
|
waives an uncured default in the payment of principal of or interest on the senior debt securities (except in the case of a
rescission of acceleration as described above);
|
|
·
|
changes the provisions relating to the waiver of past defaults or changes or impairs the right of holders to receive payment
or to institute suit for the enforcement of any payment or conversion of any senior debt securities of such series on or after
the due date therefor;
|
|
·
|
modifies any of the provisions of these restrictions on amendments and modifications, except to increase any required percentage
or to provide that certain other provisions cannot be modified or waived without the consent of the holder of each senior debt
security of such series affected by the modification; or
|
|
·
|
reduces the above-stated percentage of outstanding senior debt securities of such series whose holders must consent to a supplemental
indenture or modifies or amends or waives certain provisions of or defaults under the senior indenture.
|
It shall not be necessary for the holders to approve the particular
form of any proposed amendment, supplement or waiver, but it shall be sufficient if the holders’ consent approves the substance
thereof. After an amendment, supplement or waiver of the senior indenture in accordance with the provisions described in this section
becomes
effective, the trustee must give to the holders affected thereby
certain notice briefly describing the amendment, supplement or waiver. Any failure by the trustee to give such notice, or any defect
therein, shall not, however, in any way impair or affect the validity of any such amendment, supplemental indenture or waiver.
No
Personal Liability of Incorporators, Stockholders, Officers, Directors. The senior indenture provides that no recourse
shall be had under any obligation, covenant or agreement of ours in the senior indenture or any supplemental indenture, or in any
of the senior debt securities or because of the creation of any indebtedness represented thereby, against any of our incorporators,
stockholders, officers or directors, past, present or future, or of any predecessor or successor entity thereof under any law,
statute or constitutional provision or by the enforcement of any assessment or by any legal or equitable proceeding or otherwise.
Each holder, by accepting the senior debt securities, waives and releases all such liability.
Concerning
the Trustee. The senior indenture provides that, except during the continuance of an event of default, the trustee will
not be liable except for the performance of such duties as are specifically set forth in the senior indenture. If an event of default
has occurred and is continuing, the trustee will exercise such rights and powers vested in it under the senior indenture and will
use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct
of such person’s own affairs.
The senior indenture and the provisions of the Trust Indenture
Act incorporated by reference therein contain limitations on the rights of the trustee thereunder, should it become a creditor
of ours or any of our subsidiaries, to obtain payment of claims in certain cases or to realize on certain property received by
it in respect of any such claims, as security or otherwise. The trustee is permitted to engage in other transactions, provided
that if it acquires any conflicting interest (as defined in the Trust Indenture Act), it must eliminate such conflict or resign.
We may have normal banking relationships with the senior trustee
in the ordinary course of business.
Unclaimed
Funds. All funds deposited with the trustee or any paying agent for the payment of principal, premium, interest
or additional amounts in respect of the senior debt securities that remain unclaimed for two years after the date upon which such
principal, premium or interest became due and payable will be repaid to us. Thereafter, any right of any holder of senior debt
securities to such funds shall be enforceable only against us, and the trustee and paying agents will have no liability therefor.
Governing
Law. The senior indenture and the senior debt securities will be governed by, and construed in accordance with,
the internal laws of the State of New York.
Certain Terms of the Subordinated Debt Securities
Other than the terms of the subordinated indenture and subordinated
debt securities relating to subordination or otherwise as described in the prospectus supplement relating to a particular series
of subordinated debt securities, the terms of the subordinated indenture and subordinated debt securities are identical in all
material respects to the terms of the senior indenture and senior debt securities.
Additional or different subordination terms may be specified
in the prospectus supplement applicable to a particular series.
Subordination.
The indebtedness evidenced by the subordinated debt securities is subordinate to the prior payment in full of all of our
senior indebtedness, as defined in the subordinated indenture. During the continuance beyond any applicable grace period of
any default in the payment of principal, premium, interest or any other payment due on any
of our senior indebtedness, we may
not make any payment of principal of or interest on the subordinated debt securities (except for certain sinking fund
payments). In addition, upon any payment or distribution of our assets upon any dissolution, winding-up, liquidation or
reorganization, the payment of the principal of and interest on the subordinated debt securities will be subordinated to the
extent provided in the subordinated indenture in right of payment to the prior payment in full of all our senior
indebtedness. Because of this subordination, if we dissolve or otherwise liquidate, holders of our subordinated debt
securities may receive less, ratably, than holders of our senior indebtedness. The subordination provisions do not prevent
the occurrence of an event of default under the subordinated indenture.
The term “senior indebtedness” of a person means
with respect to such person the principal of, premium, if any, interest on, and any other payment due pursuant to any of the following,
whether outstanding on the date of the subordinated indenture or incurred by that person in the future:
|
·
|
all of the indebtedness of that person for money borrowed;
|
|
·
|
all of the indebtedness of that person evidenced by notes, debentures, bonds or other securities sold by that person for money;
|
|
·
|
all of the lease obligations that are capitalized on the books of that person in accordance with generally accepted accounting
principles;
|
|
·
|
all indebtedness of others of the kinds described in the first two bullet points above and all lease obligations of others
of the kind described in the third bullet point above that the person, in any manner, assumes or guarantees or that the person
in effect guarantees through an agreement to purchase, whether that agreement is contingent or otherwise; and
|
|
·
|
all renewals, extensions or refundings of indebtedness of the kinds described in the first, second or fourth bullet point above
and all renewals or extensions of leases of the kinds described in the third or fourth bullet point above;
|
unless, in the case of any particular indebtedness, renewal,
extension or refunding, the instrument creating or evidencing it or the assumption or guarantee relating to it expressly provides
that such indebtedness, renewal, extension or refunding is not superior in right of payment to the subordinated debt securities.
Our senior debt securities constitute senior indebtedness for purposes of the subordinated debt indenture.
DESCRIPTION OF OUR CAPITAL STOCK
The following description of our capital stock and provisions
of our certificate of incorporate, bylaws and the Delaware General Corporate Law, or DGCL, are summaries and are qualified in their
entirety by reference to the certificate of incorporation and the bylaws. We have filed copies of these documents with the SEC
as exhibits to our registration statement, of which this prospectus forms a part.
Our authorized capital stock consists of 200,000,000 shares
of our common stock, par value $0.001 per share, and 5,000,000 shares of our preferred stock, par value $0.001 per share, all of
which preferred stock is undesignated. As of May 10, 2018, we had 48,390,072 shares of our common stock issued and outstanding
held by 35 stockholders of record. This number does not include beneficial owners whose shares were held in street name.
Common Stock
Holders of our common stock are entitled to one vote for each
share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Each election of directors
by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders
of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to
any preferential dividend rights of then outstanding preferred stock.
In the event of our liquidation or dissolution, the holders
of our common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment
of all debts and other liabilities and subject to the prior rights of any of our then outstanding preferred stock. Holders of our
common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders
of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred
stock that we may designate and issue in the future.
Preferred Stock
We are authorized to issue “blank check” preferred
stock, which may be issued in one or more series upon authorization of our board of directors. Our board of directors is authorized
to fix the designation of the series, the number of authorized shares of the series, dividend rights and terms, conversion rights,
voting rights, redemption rights and terms, liquidation preferences and any other rights, powers, preferences and limitations applicable
to each series of preferred stock. The authorized shares of our preferred stock are available for issuance without further action
by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities
may be listed. If the approval of our stockholders is not required for the issuance of shares of our preferred stock, our board
may determine not to seek stockholder approval. The specific terms of any series of preferred stock offered pursuant to this prospectus
will be described in the prospectus supplement relating to that series of preferred stock.
A series of our preferred stock could, depending on the terms
of such series, impede the completion of a merger, tender offer or other takeover attempt. Our board of directors will make any
determination to issue preferred shares based upon its judgment as to the best interests of our stockholders. Our directors, in
so acting, could issue preferred stock having terms that could discourage an acquisition attempt through which an acquirer may
be able to change the composition of our board of directors, including a tender offer or other transaction that some, or a majority,
of our stockholders might believe to be in their best interests or in which stockholders might receive a premium for their stock
over the then-current market price of the stock.
The preferred stock has the terms described below unless otherwise
provided in the prospectus supplement relating to a particular series of preferred stock. You should read the prospectus supplement
relating to the particular series of preferred stock being offered for specific terms, including:
|
·
|
the designation and stated value per share of the preferred stock and the number of shares offered;
|
|
·
|
the amount of liquidation preference per share;
|
|
·
|
the price at which the preferred stock will be issued;
|
|
·
|
the dividend rate, or method of calculation of dividends, the dates on which dividends will be payable, whether dividends will
be cumulative or noncumulative and, if cumulative, the dates from which dividends will commence to accumulate;
|
|
·
|
any redemption or sinking fund provisions;
|
|
·
|
if other than the currency of the United States, the currency or currencies including composite currencies in which the preferred
stock is denominated and/or in which payments will or may be payable;
|
|
·
|
a discussion of any material U.S. federal income tax considerations applicable to the preferred stock;
|
|
·
|
any conversion provisions;
|
|
·
|
whether we have elected to offer depositary shares as described under “Description of Depositary Shares”; and
|
|
·
|
any other rights, preferences, privileges, limitations and restrictions on the preferred stock.
|
The preferred stock will, when issued, be fully paid and non-assessable.
Unless otherwise specified in the prospectus supplement, each series of preferred stock will rank equally as to dividends and liquidation
rights in all respects with each other series of preferred stock. The rights of holders of shares of each series of preferred stock
will be subordinate to those of our general creditors.
As described under “Description of Depositary Shares,”
we may, at our option, with respect to any series of preferred stock, elect to offer fractional interests in shares of preferred
stock, and provide for the issuance of depositary receipts representing depositary shares, each of which will represent a fractional
interest in a share of the series of preferred stock. The fractional interest will be specified in the prospectus supplement relating
to a particular series of preferred stock.
Rank.
Unless otherwise specified in the prospectus supplement, the preferred stock will, with respect to dividend rights and
rights upon our liquidation, dissolution or winding up of our affairs, rank:
|
·
|
senior to our common stock and to all equity securities ranking junior to such preferred stock with respect to dividend rights
or rights upon our liquidation, dissolution or winding up of our affairs;
|
|
·
|
on a parity with all equity securities issued by us, the terms of which specifically provide that such equity securities rank
on a parity with the preferred stock with respect to dividend rights or rights upon our liquidation, dissolution or winding up
of our affairs; and
|
|
·
|
junior to all equity securities issued by us, the terms of which specifically provide that such equity securities rank senior
to the preferred stock with respect to dividend rights or rights upon our liquidation, dissolution or winding up of our affairs.
|
The term “equity securities” does not include convertible
debt securities.
Dividends.
Holders of the preferred stock of each series will be entitled to receive, when, as and if declared by our board of directors,
cash dividends at such rates and on such dates described in the prospectus supplement. Different series of preferred stock may
be entitled to dividends at different rates or based on different methods of calculation. The dividend rate may be fixed or variable
or both. Dividends will be payable to the holders of record as they appear on our stock books on record dates fixed by our board
of directors, as specified in the applicable prospectus supplement.
Dividends on any series of preferred stock may be cumulative
or noncumulative, as described in the applicable prospectus supplement. If our board of directors does not declare a dividend payable
on a dividend payment date on any series of noncumulative preferred stock, then the holders of that noncumulative preferred stock
will have no right to receive a dividend for that dividend payment date, and we will have no obligation to pay the dividend accrued
for that period, whether or not dividends on that series are declared payable on any future dividend payment dates. Dividends on
any series of cumulative preferred stock will accrue from the date we initially issue shares of such series or such other date
specified in the applicable prospectus supplement.
No dividends may be declared or paid or funds set apart for
the payment of any dividends on any parity securities unless full dividends have been paid or set apart for payment on the preferred
stock. If full dividends are not paid, the preferred stock will share dividends pro rata with the parity securities.
No dividends may be declared or paid or funds set apart for
the payment of dividends on any junior securities unless full dividends for all dividend periods terminating on or prior to the
date of the declaration or payment will have been paid or declared and a sum sufficient for the payment set apart for payment on
the preferred stock.
Liquidation
Preference. Upon any voluntary or involuntary liquidation, dissolution or winding up of our affairs, then, before we
make any distribution or payment to the holders of any common stock or any other class or series of our capital stock ranking junior
to the preferred stock in the distribution of assets upon any liquidation, dissolution or winding up of our affairs, the holders
of each series of preferred stock shall be entitled to receive out of assets legally available for distribution to stockholders,
liquidating distributions in the amount of the liquidation preference per share set forth in the prospectus supplement, plus any
accrued and unpaid dividends thereon. Such dividends will not include any accumulation in respect of unpaid noncumulative dividends
for prior dividend periods. Unless otherwise specified in the prospectus supplement, after payment of the full amount of their
liquidating distributions, the holders of preferred stock will have no right or claim to any of our remaining assets. Upon any
such voluntary or involuntary liquidation, dissolution or winding up, if our available assets are insufficient to pay the amount
of the liquidating distributions on all outstanding preferred stock and the corresponding amounts payable on all other classes
or series of our capital stock ranking on parity with the preferred stock and all other such classes or series of shares of capital
stock ranking on parity with the preferred stock in the distribution of assets, then the holders of the preferred stock and all
other such classes or series of capital stock will share ratably in any such distribution of assets in proportion to the full liquidating
distributions to which they would otherwise be entitled.
Upon any such liquidation, dissolution or winding up and if
we have made liquidating distributions in full to all holders of preferred stock, we will distribute our remaining assets among
the holders of any other classes or series of capital stock ranking junior to the preferred stock according to their respective
rights and preferences and, in each case, according to their respective number of shares. For such purposes, our consolidation
or merger with or into any other corporation, trust or entity, or the sale, lease or conveyance of all or substantially all of
our property or assets will not be deemed to constitute a liquidation, dissolution or winding up of our affairs.
Redemption.
If so provided in the applicable prospectus supplement, the preferred stock will be subject to mandatory redemption or redemption
at our option, as a whole or in part, in each case upon the terms, at the times and at the redemption prices set forth in such
prospectus supplement.
The prospectus supplement relating to a series of
preferred stock that is subject to mandatory redemption will specify the number of shares of preferred stock that shall be
redeemed by us in each year commencing after a date to be specified, at a redemption price per share to be specified,
together with an amount equal to all accrued and unpaid dividends thereon to the date of redemption. Unless the shares have a
cumulative dividend, such accrued dividends
will not include any accumulation in respect of unpaid dividends for prior
dividend periods. We may pay the redemption price in cash or other property, as specified in the applicable prospectus
supplement. If the redemption price for preferred stock of any series is payable only from the net proceeds of the issuance
of shares of our capital stock, the terms of such preferred stock may provide that, if no such shares of our capital stock
shall have been issued or to the extent the net proceeds from any issuance are insufficient to pay in full the aggregate
redemption price then due, such preferred stock shall automatically and mandatorily be converted into the applicable shares
of our capital stock pursuant to conversion provisions specified in the applicable prospectus supplement. Notwithstanding the
foregoing, we will not redeem any preferred stock of a series unless:
|
·
|
if that series of preferred stock has a cumulative dividend, we have declared and paid or contemporaneously declare and pay
or set aside funds to pay full cumulative dividends on the preferred stock for all past dividend periods and the then current dividend
period; or
|
|
·
|
if such series of preferred stock does not have a cumulative dividend, we have declared and paid or contemporaneously declare
and pay or set aside funds to pay full dividends for the then current dividend period.
|
In addition, we will not acquire any preferred stock of a series
unless:
|
·
|
if that series of preferred stock has a cumulative dividend, we have declared and paid or contemporaneously declare and pay
or set aside funds to pay full cumulative dividends on all outstanding shares of such series of preferred stock for all past dividend
periods and the then current dividend period; or
|
|
·
|
if that series of preferred stock does not have a cumulative dividend, we have declared and paid or contemporaneously declare
and pay or set aside funds to pay full dividends on the preferred stock of such series for the then current dividend period.
|
However, at any time we may purchase or acquire preferred stock
of that series (1) pursuant to a purchase or exchange offer made on the same terms to holders of all outstanding preferred
stock of such series or (2) by conversion into or exchange for shares of our capital stock ranking junior to the preferred
stock of such series as to dividends and upon liquidation.
If fewer than all of the outstanding shares of preferred stock
of any series are to be redeemed, we will determine the number of shares that may be redeemed pro rata from the holders of record
of such shares in proportion to the number of such shares held or for which redemption is requested by such holder or by any other
equitable manner that we determine. Such determination will reflect adjustments to avoid redemption of fractional shares.
Unless otherwise specified in the prospectus supplement, we
will mail notice of redemption at least 30 days but not more than 60 days before the redemption date to each holder of record of
preferred stock to be redeemed at the address shown on our stock transfer books. Each notice shall state:
|
·
|
the number of shares and series of preferred stock to be redeemed;
|
|
·
|
the place or places where certificates for such preferred stock are to be surrendered for payment of the redemption price;
|
|
·
|
that dividends on the shares to be redeemed will cease to accrue on such redemption date;
|
|
·
|
the date on which the holder’s conversion rights, if any, as to such shares shall terminate; and
|
|
·
|
the specific number of shares to be redeemed from each such holder if fewer than all the shares of any series are to be redeemed.
|
If notice of redemption has been given and we have set aside
the funds necessary for such redemption in trust for the benefit of the holders of any shares called for redemption, then from
and after the redemption date, dividends will cease to accrue on such shares, and all rights of the holders of such shares will
terminate, except the right to receive the redemption price.
Voting
Rights. Holders of preferred stock will not have any voting rights, except as required by law or as indicated in
the applicable prospectus supplement.
Unless otherwise provided for under the terms of any series
of preferred stock, no consent or vote of the holders of shares of preferred stock or any series thereof shall be required for
any amendment to our certificate of incorporation that would increase the number of authorized shares of preferred stock or the
number of authorized shares of any series thereof or decrease the number of authorized shares of preferred stock or the number
of authorized shares of any series thereof (but not below the number of authorized shares of preferred stock or such series, as
the case may be, then outstanding).
Conversion
Rights. The terms and conditions, if any, upon which any series of preferred stock is convertible into our common stock
will be set forth in the applicable prospectus supplement relating thereto. Such terms will include the number of shares of common
stock into which the shares of preferred stock are convertible, the conversion price, rate or manner of calculation thereof, the
conversion period, provisions as to whether conversion will be at our option or at the option of the holders of the preferred stock,
the events requiring an adjustment of the conversion price and provisions affecting conversion in the event of the redemption.
Common Stock Warrants
As of May 10, 2018, we had outstanding:
|
·
|
warrants held by Silicon Valley Bank, or the SVB warrants, to purchase up to an aggregate of 55,000 shares of our common stock,
at a weighted-average exercise price of $11.44 per share;
|
|
·
|
warrants held by certain of our investors issued in connection with a publicly registered follow-on offering, or the November 2017
warrants, to purchase up to aggregate of 4,349,875 shares of our common stock, at a weighted-average exercise price of $0.80 per
share; and
|
|
·
|
warrants held by certain of our investors issued in connection with a private placement made in reliance on the exemption provided
by Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder as transactions not involving
a public offering, or the March 2018 warrants, to purchase up to an aggregate 7,968,128 shares of our common stock, at a weighted-average
exercise price of $1.20 per share.
|
These warrants provide for adjustments in the event of specified
mergers, reorganizations, reclassifications, stock dividends, stock splits or other changes in our corporate structure. The SVB
warrants are exercisable until November 24, 2024 and will be exercised automatically on a net issuance basis if not exercised
prior to the expiration date and if the then-current fair market value of one share of our common stock is greater than the exercise
price then in effect. The November 2017 warrants are exercisable until November 1, 2022 and as of May 10, 2018,
5,650,125 of the November 2017 warrants had been exercised. The March 2018 warrants are exercisable until March 23,
2023 and as of May 10, 2018, none of the March 2018 warrants had been exercised.
Options to Purchase our Common Stock
As of May 10, 2018, options to purchase an aggregate of
3,564,770 shares of our common stock, at a weighted-average exercise price of $2.72 per share, were outstanding.
Delaware Anti-Takeover Law and Certain Charter and Bylaw
provisions
The following summary of certain provisions of Delaware law
and of our certificate of incorporation and bylaws does not purport to be complete and is subject to and qualified in its entirety
by reference to Delaware law and to our certificate of incorporation and bylaws, copies of which are filed with the SEC as exhibits
to the registration statement of which this prospectus forms a part.
Delaware
Law. We are subject to Section 203 of the DGCL. Subject to certain exceptions, Section 203 prevents a publicly
held Delaware corporation from engaging in a “business combination” with any “interested stockholder” for
three years following the date that the person became an interested stockholder, unless either the interested stockholder attained
such status with the approval of our board of directors, the business combination is approved by our board of directors and stockholders
in a prescribed manner or the interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in
which it became an interested stockholder. A “business combination” includes, among other things, a merger or consolidation
involving us and the “interested stockholder” and the sale of more than 10% of our assets. In general, an “interested
stockholder” is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person
affiliated with or controlling or controlled by such entity or person.
The restrictions in Section 203 do not apply to corporations
that have elected, in the manner provided in Section 203, not to be subject to Section 203 of the DGCL or, with certain
exceptions, which do not have a class of voting stock that is listed on a national securities exchange or held of record by more
than 2,000 stockholders. Our certificate of incorporation and bylaws do not opt out of Section 203.
Section 203 could delay or prohibit mergers or other takeover
or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction
may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.
Staggered
Board; Removal of Directors. Our certificate of incorporation and our bylaws divide our board of directors into three
classes with staggered three-year terms. In addition, our certificate of incorporation and our bylaws provide that directors may
be removed only for cause and only by the affirmative vote of the holders of 75% of our shares of common stock present in person
or by proxy and entitled to vote. Under our certificate of incorporation and bylaws, any vacancy on our board of directors, including
a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then
in office. Furthermore, our certificate of incorporation provides that the authorized number of directors may be changed only
by the resolution of our board of directors. The classification of our board of directors and the limitations on the ability of
our stockholders to remove directors, change
the authorized number of directors and fill vacancies could make it more difficult
for a third party to acquire, or discourage a third party from seeking to acquire, control of our company.
Stockholder
Action; Special Meeting of Stockholders; Advance Notice Requirements for Stockholder Proposals and Director Nominations.
Our certificate of incorporation and our bylaws provide that any action required or permitted to be taken by our stockholders at
an annual meeting or special meeting of stockholders may only be taken if it is properly brought before such meeting and may not
be taken by written action in lieu of a meeting. Our certificate of incorporation and our bylaws also provide that, except as otherwise
required by law, special meetings of the stockholders can only be called by the chairman of our board of directors, our chief executive
officer or our board of directors. In addition, our bylaws establish an advance notice procedure for stockholder proposals to be
brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors.
Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before
the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting
who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder’s
intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder
meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. These provisions
also could discourage a third party from making a tender offer for our common stock because even if the third party acquired a
majority of our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving
a merger, only at a duly called stockholders meeting and not by written consent.
Super-Majority
Voting. The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter
is required to amend a corporation’s certificate of incorporation or bylaws unless a corporation’s certificate of incorporation
or bylaws, as the case may be, requires a greater percentage. Our bylaws may be amended or repealed by a majority vote of our board
of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to
cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all
our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt any provisions
inconsistent with any of the provisions of our certificate of incorporation described above.
Registration Rights
Prior
Holders of Series B Redeemable Convertible Preferred Stock. On February 9, 2010, we entered into an investors’
rights agreement, subsequently amended on April 23, 2012, which we refer to as the Investor Rights Agreement, with holders
of our then-outstanding preferred stock. Under the Investor Rights Agreement, if holders of at least 25% of shares of common stock
under the agreement request that we register their shares which represent an anticipated net aggregate offering price of at least
$5 million, then we shall file a registration statement under the Securities Act covering such shares. In addition, if we propose
to register for our own account any of our securities under the Securities Act, holders of at least 10% of shares of common stock
under the agreement have the right to require us to use our best efforts to register all or a portion of their shares subject to
the agreement and still held by them in such registration statement. If not otherwise exercised, the rights under the Investor
Rights Agreement will expire on February 6, 2019, the fifth anniversary of the closing of our IPO.
2014
Private Placement. On December 2, 2014, we entered into a registration rights agreement with certain holders
of our common stock in connection with a private placement transaction. Under the registration rights agreement for the
private placement, we were required to file a registration statement with the SEC, covering the resale of the 1,743,680
shares of common stock issued in the private placement and the 871,840 shares of common stock issuable
upon exercise of the
warrants issued in the private placement. A registration statement relating to such shares was filed on
December 19, 2014 and declared effective by the SEC on December 31, 2014.
Shares
Issued in our Acquisition of Viventia Bio Inc. In connection with our acquisition of Viventia, we entered into a registration
rights agreement dated September 20, 2016, or the Registration Rights Agreement, with Clairmark Investments Ltd., or Clairmark,
a former stockholder of Viventia and an affiliate of Leslie Dan, one of our directors, which acquired shares of our common stock
in the acquisition. Under the Registration Rights Agreement, if Clairmark requests that we register at least 1,791,164 shares of
our common stock which represent an anticipated net aggregate offering price of at least $5 million, then we shall file a registration
statement under the Securities Act covering such shares. In addition, if we propose to register for our own account any of our
securities under the Securities Act, Clairmark has the right to require us to use our best efforts to register all or a portion
of the shares acquired in the acquisition and still held by it in such registration statement. If not otherwise exercised, the
rights under the Registration Rights Agreement described below will expire on September 20, 2021.
2018
Private Placement. On Mach 21, 2018, we entered into a Securities Purchase Agreement with the selling stockholders pursuant
to which we sold, among other securities, 7,968,128 common stock purchase warrants in a private placement. On April 27, 2018,
we amended the Securities Purchase Agreement to allow us to satisfy our obligation to register the shares of common stock issuable
upon exercise of the warrants by filing a registration statement on Form S-3. We refer to the Securities Purchase Agreement,
as amended, as the “2018 Purchase Agreement.” Under the 2018 Purchase Agreement, we were required to file a registration
statement on Form S-3 with the SEC no later than May 5, 2018 covering the resale of the 7,968,128 shares of our common
stock issuable upon exercise of the warrants sold in the private placement. A registration statement relating to such shares was
filed on May 4, 2018 and declared effective by the SEC on May 11, 2018.
Expenses.
Pursuant to the Investor Rights Agreement, the Registration Rights Agreement and the 2018 Purchase Agreement, we are required to
pay all registration expenses, including the fees and expenses of one counsel to represent such holders of our common stock, other
than any underwriting discounts, selling commissions and fees and expenses of such holder’s own counsel related to any demand
or incidental registration. We are not required to pay registration expenses if the registration request under the Investor Rights
Agreement or the Registration Rights Agreement is withdrawn at the request of such holders, unless the withdrawal is due to discovery
of a materially adverse change in our business after the initiation of such registration request.
The Investor Rights Agreement and the Registration Rights Agreement
contain customary cross-indemnification provisions, pursuant to which we are obligated to indemnify such holders in the event of
material misstatements or omissions in the registration statement attributable to us or any violation or alleged violation whether
by action or inaction by us under the Securities Act, the Exchange Act, any state securities or Blue Sky law or any rule or
regulation promulgated under the Securities Act, the Exchange Act or any state securities or Blue Sky law in connection with such
registration statement or the qualification or compliance of the offering, and such holders are obligated to indemnify us for material
misstatements or omissions in the registration statement attributable to it.
All applicable registration rights with respect to the registration
statement of which this prospectus forms a part have been waived.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Computershare
Trust Company, Inc.
Stock Market Listing
Our common stock is listed for trading on the Nasdaq Global
Market under the symbol “EBIO.”
DESCRIPTION OF OUR DEPOSITARY SHARES
General
We may, at our option, elect to offer fractional shares of preferred
stock, which we call depositary shares, rather than full shares of preferred stock. If we do, we will issue to the public receipts,
called depositary receipts, for depositary shares, each of which will represent a fraction, to be described in the applicable prospectus
supplement, of a share of a particular series of preferred stock. Unless otherwise provided in the prospectus supplement, each
owner of a depositary share will be entitled, in proportion to the applicable fractional interest in a share of preferred stock
represented by the depositary share, to all the rights and preferences of the preferred stock represented by the depositary share.
Those rights include dividend, voting, redemption, conversion and liquidation rights.
The shares of preferred stock underlying the depositary shares
will be deposited with a bank or trust company selected by us to act as depositary under a deposit agreement between us, the depositary
and the holders of the depositary receipts. The depositary will be the transfer agent, registrar and dividend disbursing agent
for the depositary shares.
The depositary shares will be evidenced by depositary receipts
issued pursuant to the deposit agreement. Holders of depositary receipts agree to be bound by the deposit agreement, which requires
holders to take certain actions such as filing proof of residence and paying certain charges.
The summary of terms of the depositary shares contained in this
prospectus is not a complete description of the terms of the depository shares. You should refer to the form of the deposit agreement,
our certificate of incorporation and the certificate of designation for the applicable series of preferred stock that are, or will
be, filed with the SEC.
Dividends and Other Distributions
The depositary will distribute all cash dividends or other cash
distributions, if any, received in respect of the preferred stock underlying the depositary shares to the record holders of depositary
shares in proportion to the numbers of depositary shares owned by those holders on the relevant record date. The relevant record
date for depositary shares will be the same date as the record date for the underlying preferred stock.
If there is a distribution other than in cash, the depositary
will distribute property (including securities) received by it to the record holders of depositary shares, unless the depositary
determines that it is not feasible to make the distribution. If this occurs, the depositary may, with our approval, adopt another
method for the distribution, including selling the property and distributing the net proceeds from the sale to the holders.
Liquidation Preference
If a series of preferred stock underlying the depositary shares
has a liquidation preference, in the event of the voluntary or involuntary liquidation, dissolution or winding up of us, holders
of depositary shares will be entitled to receive the fraction of the liquidation preference accorded each share of the applicable
series of preferred stock, as set forth in the applicable prospectus supplement.
Withdrawal of Stock
Unless the related depositary shares have been previously called
for redemption, upon surrender of the depositary receipts at the office of the depositary, the holder of the depositary shares
will be entitled to delivery, at the office of the depositary to or upon his or her order, of the number of whole shares of the
preferred stock and any money or other property represented by the depositary shares. If the depositary receipts delivered by the
holder evidence a number of depositary shares in excess of the number of depositary shares representing the number of whole shares
of preferred stock to be withdrawn, the depositary will deliver to the holder at the same time a new depositary receipt evidencing
the excess number of depositary shares. In no event will the depositary deliver fractional shares of preferred stock upon surrender
of depositary receipts. Holders of preferred stock thus withdrawn may not thereafter deposit those shares under the deposit agreement
or receive depositary receipts evidencing depositary shares therefor.
Redemption of Depositary Shares
Whenever we redeem shares of preferred stock held by the depositary,
the depositary will redeem as of the same redemption date the number of depositary shares representing shares of the preferred
stock so redeemed, so long as we have paid in full to the depositary the redemption price of the preferred stock to be redeemed
plus an amount equal to any accumulated and unpaid dividends on the preferred stock to the date fixed for redemption. The redemption
price per depositary share will be equal to the redemption price and any other amounts per share payable on the preferred stock
multiplied by the fraction of a share of preferred stock represented by one depositary share. If less than all the depositary shares
are to be redeemed, the depositary shares to be redeemed will be selected by lot or pro rata or by any other equitable method as
may be determined by the depositary.
After the date fixed for redemption, depositary shares called
for redemption will no longer be deemed to be outstanding and all rights of the holders of depositary shares will cease, except
the right to receive the monies payable upon redemption and any money or other property to which the holders of the depositary
shares were entitled upon redemption upon surrender to the depositary of the depositary receipts evidencing the depositary shares.
Voting the Preferred Stock
Upon receipt of notice of any meeting at which the holders of
the preferred stock are entitled to vote, the depositary will mail the information contained in the notice of meeting to the record
holders of the depositary receipts relating to that preferred stock. The record date for the depositary receipts relating to the
preferred stock will be the same date as the record date for the preferred stock. Each record holder of the depositary shares on
the record date will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the number of
shares of preferred stock represented by that holder’s depositary shares. The depositary will endeavor, insofar as practicable,
to vote the number of shares of preferred stock represented by the depositary shares in accordance with those instructions, and
we will agree to take all action that may be deemed necessary by the depositary in order to enable the depositary to do so. The
depositary will not vote any shares of preferred stock except to the extent it receives specific instructions from the holders
of depositary shares representing that number of shares of preferred stock.
Charges of Depositary
We will pay all transfer and other taxes and governmental
charges arising solely from the existence of the depositary arrangements. We will pay charges of the depositary in connection
with the initial deposit of the preferred stock and any redemption of the preferred stock. Holders of depositary receipts
will pay transfer, income and other taxes and
governmental charges and such other charges (including those in connection with
the receipt and distribution of dividends, the sale or exercise of rights, the withdrawal of the preferred stock and the
transferring, splitting or grouping of depositary receipts) as are expressly provided in the deposit agreement to be for
their accounts. If these charges have not been paid by the holders of depositary receipts, the depositary may refuse to
transfer depositary shares, withhold dividends and distributions and sell the depositary shares evidenced by the depositary
receipt.
Amendment and Termination of the Deposit Agreement
The form of depositary receipt evidencing the depositary shares
and any provision of the deposit agreement may be amended by agreement between us and the depositary. However, any amendment that
materially and adversely alters the rights of the holders of depositary shares, other than fee changes, will not be effective unless
the amendment has been approved by the holders of a majority of the outstanding depositary shares. The deposit agreement may be
terminated by the depositary or us only if:
|
·
|
all outstanding depositary shares have been redeemed; or
|
|
·
|
there has been a final distribution of the preferred stock in connection with our dissolution and such distribution has been
made to all the holders of depositary shares.
|
Resignation and Removal of Depositary
The depositary may resign at any time by delivering to us notice
of its election to do so, and we may remove the depositary at any time. Any resignation or removal of the depositary will take
effect upon our appointment of a successor depositary and its acceptance of such appointment. The successor depositary must be
appointed within 60 days after delivery of the notice of resignation or removal and must be a bank or trust company having its
principal office in the United States and having the requisite combined capital and surplus as set forth in the applicable agreement.
Notices
The depositary will forward to holders of depositary receipts
all notices, reports and other communications, including proxy solicitation materials received from us, that are delivered to the
depositary and that we are required to furnish to the holders of the preferred stock. In addition, the depositary will make available
for inspection by holders of depositary receipts at the principal office of the depositary, and at such other places as it may
from time to time deem advisable, any reports and communications we deliver to the depositary as the holder of preferred stock.
Limitation of Liability
Neither we nor the depositary will be liable if either we or
it is prevented or delayed by law or any circumstance beyond its control in performing its obligations. Our obligations and those
of the depositary will be limited to performance in good faith of our and their duties thereunder. We and the depositary will not
be obligated to prosecute or defend any legal proceeding in respect of any depositary shares or preferred stock unless satisfactory
indemnity is furnished. We and the depositary may rely upon written advice of counsel or accountants, on information provided by
persons presenting preferred stock for deposit, holders of depositary receipts or other persons believed to be competent to give
such information and on documents believed to be genuine and to have been signed or presented by the proper party or parties.
DESCRIPTION OF OUR WARRANTS
We may issue warrants to purchase common stock, preferred stock,
depositary shares or debt securities. We may offer warrants separately or together with one or more additional warrants, common
stock, preferred stock, depositary shares or debt securities, or any combination of those securities in the form of units, as described
in the applicable prospectus supplement. If we issue warrants as part of a unit, the accompanying prospectus supplement will specify
whether those warrants may be separated from the other securities in the unit prior to the expiration date of the warrants. The
applicable prospectus supplement will also describe the following terms of any warrants:
|
·
|
the specific designation and aggregate number of, and the offering price at which we will issue, the warrants;
|
|
·
|
the currency or currency units in which the offering price, if any, and the exercise price are payable;
|
|
·
|
the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may
not continuously exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants;
|
|
·
|
whether the warrants are to be sold separately or with other securities as parts of units;
|
|
·
|
whether the warrants will be issued in definitive or global form or in any combination of these forms, although, in any case,
the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit;
|
|
·
|
any applicable material U.S. federal income tax consequences;
|
|
·
|
the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents,
registrars or other agents;
|
|
·
|
the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities
exchange;
|
|
·
|
the designation and terms of any equity securities purchasable upon exercise of the warrants;
|
|
·
|
the designation, aggregate principal amount, currency and terms of any debt securities that may be purchased upon exercise
of the warrants;
|
|
·
|
if applicable, the designation and terms of the preferred stock or depositary shares with which the warrants are issued and
the number of warrants issued with each security;
|
|
·
|
if applicable, the date from and after which any warrants issued as part of a unit and the related debt securities, preferred
stock, depositary shares or common stock will be separately transferable;
|
|
·
|
the number of shares of common stock, preferred stock or depositary shares purchasable upon exercise of a warrant and the price
at which those shares may be purchased;
|
|
·
|
if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
|
|
·
|
information with respect to book-entry procedures, if any;
|
|
·
|
the anti-dilution provisions of, and other provisions for changes to or adjustment in the exercise price of, the warrants,
if any;
|
|
·
|
any redemption or call provisions; and
|
|
·
|
any additional terms of the warrants, including terms, procedures and limitations relating to the exchange or exercise of the
warrants.;
|
Description of Outstanding Warrants
As of May 10, 2018, there were 12,373,003 warrants to purchase
shares of our common stock outstanding. See “Description of Our Capital Stock - Common Stock Warrants.”
DESCRIPTION OF OUR UNITS
The following, together with the additional information we may
include in the applicable prospectus supplement or free writing prospectus, summarizes the material terms and provisions of the
units that we may offer under this prospectus. While the terms summarized below will apply generally to any units we may offer,
we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement or free writing
prospectus.
We may, from time to time, issue units comprised of one or more
of the other securities that may be offered under this prospectus, in any combination. Each unit will be issued so that the holder
of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations
of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included
in the unit may not be held or transferred separately at any time, or at any time before a specified date.
We will describe in the applicable prospectus supplement or
free writing prospectus the terms of the series of units, including:
|
•
|
the material terms of the units and of the securities comprising the units, including whether and under what circumstances
those securities may be held or transferred separately;
|
|
•
|
the rights and obligations of the unit agent, if any;
|
|
•
|
any material provisions relating to the issuance, payment, settlement, transfer or exchange of the units or of the securities
comprising the units; and
|
|
•
|
any material provisions of the governing unit agreement that differ from those described above.
|
Issuance in Series
We may issue units in such amounts and in numerous distinct
series as we determine.
FORMS OF SECURITIES
Each debt security, depositary share, warrant, unit and security
right may be represented either by a certificate issued in definitive form to a particular investor or by one or more global securities
representing the entire issuance of securities. Unless the applicable prospectus supplement provides otherwise, certificated securities
in definitive form and global securities will be issued in registered form. Definitive securities name you or your nominee as the
owner of the security, and in order to transfer or exchange these securities or to receive payments other than interest or other
interim payments, you or your nominee must physically deliver the securities to the trustee, registrar, paying agent or other agent,
as applicable. Global securities name a depositary or its nominee as the owner of the debt securities, depositary shares, warrants
or units represented by these global securities. The depositary maintains a computerized system that will reflect each investor’s
beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company
or other representative, as we explain more fully below.
Global Securities
We may issue the debt securities, depositary shares, warrants
and units in the form of one or more fully registered global securities that will be deposited with a depositary or its nominee
identified in the applicable prospectus supplement and registered in the name of that depositary or nominee. In those cases, one
or more global securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal
or face amount of the securities to be represented by global securities. Unless and until it is exchanged in whole for securities
in definitive registered form, a global security may not be transferred except as a whole by and among the depositary for the global
security, the nominees of the depositary or any successors of the depositary or those nominees.
If not described below, any specific terms of the depositary
arrangement with respect to any securities to be represented by a global security will be described in the prospectus supplement
relating to those securities. We anticipate that the following provisions will apply to all depositary arrangements.
Ownership of beneficial interests in a global security will
be limited to persons, called participants, that have accounts with the depositary or persons that may hold interests through participants.
Upon the issuance of a global security, the depositary will credit, on its book-entry registration and transfer system, the participants’
accounts with the respective principal or face amounts of the securities beneficially owned by the participants. Any dealers, underwriters
or agents participating in the distribution of the securities will designate the accounts to be credited. Ownership of beneficial
interests in a global security will be shown on, and the transfer of ownership interests will be effected only through, records
maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect to interests
of persons holding through participants. The laws of some states may require that some purchasers of securities take physical delivery
of these securities in definitive form. These laws may impair your ability to own, transfer or pledge beneficial interests in global
securities.
So long as the depositary, or its nominee, is the
registered owner of a global security, that depositary or its nominee, as the case may be, will be considered the sole owner
or holder of the securities represented by the global security for all purposes under the applicable indenture, deposit
agreement, warrant agreement or unit agreement. Except as described below, owners of beneficial interests in a global
security will not be entitled to have the securities represented by the global security registered in their names, will not
receive or be entitled to receive physical delivery of the securities in definitive form and will not be considered the
owners or holders of the securities under the applicable indenture, deposit agreement, warrant agreement or unit agreement.
Accordingly, each person owning a beneficial interest in a global security must rely on the procedures of the depositary for
that global security and, if that person is not a participant, on the procedures of the participant through which the person
owns its interest, to exercise any rights of a holder under the applicable indenture, deposit agreement, warrant agreement or
unit agreement. We understand that under existing industry practices, if we request any action of holders or if an owner of a
beneficial interest in a
global security desires to give or take any action that a holder is entitled to give or take under
the applicable indenture, deposit agreement, warrant agreement or unit agreement, the depositary for the global security
would authorize the participants holding the relevant beneficial interests to give or take that action, and the participants
would authorize beneficial owners owning through them to give or take that action or would otherwise act upon the
instructions of beneficial owners holding through them.
Principal, premium, if any, and interest payments on debt securities,
and any payments to holders with respect to depositary shares, warrants or units, represented by a global security registered in
the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner
of the global security. None of us, or any trustee, warrant agent, unit agent or other agent of ours, or any agent of any trustee,
warrant agent or unit agent will have any responsibility or liability for any aspect of the records relating to payments made on
account of beneficial ownership interests in the global security or for maintaining, supervising or reviewing any records relating
to those beneficial ownership interests.
We expect that the depositary for any of the securities represented
by a global security, upon receipt of any payment to holders of principal, premium, interest or other distribution of underlying
securities or other property on that registered global security, will immediately credit participants’ accounts in amounts
proportionate to their respective beneficial interests in that global security as shown on the records of the depositary. We also
expect that payments by participants to owners of beneficial interests in a global security held through participants will be governed
by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers
or registered in “street name,” and will be the responsibility of those participants.
If the depositary for any of the securities represented by a
global security is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under
the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within
90 days, we will issue securities in definitive form in exchange for the global security that had been held by the depositary.
Any securities issued in definitive form in exchange for a global security will be registered in the name or names that the depositary
gives to the relevant trustee, warrant agent, unit agent or other relevant agent of ours or theirs. It is expected that the depositary’s
instructions will be based upon directions received by the depositary from participants with respect to ownership of beneficial
interests in the global security that had been held by the depositary.
PLAN OF DISTRIBUTION
We may sell the securities being offered by this prospectus
separately or together:
|
·
|
directly to purchasers;
|
|
·
|
to or through underwriters;
|
|
·
|
through a block trade in which the broker or dealer engaged to handle the block trade will attempt to sell the securities as
agent, but may position and resell a portion of the block as principal to facilitate the transaction; or
|
|
·
|
through a combination of any of these methods of sale.
|
In addition, we may issue the securities being offered by this
prospectus as a dividend or distribution to our existing security holders. This prospectus may be used in connection with any offering
of our securities through any of these methods or other methods described in the applicable prospectus supplement or free writing
prospectus.
We may directly solicit offers to purchase securities, or agents
may be designated to solicit such offers. We will, in the prospectus supplement relating to such offering, name any agent that
could be viewed as an underwriter under the Securities Act, and describe any commissions that we must pay. Any such agent will
be acting on a best efforts basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on
a firm commitment basis.
We may effect the distribution of the securities from time to
time in one or more transactions:
|
·
|
at a fixed price, or prices, which may be changed from time to time;
|
|
·
|
at market prices prevailing at the time of sale;
|
|
·
|
at prices related to such prevailing market prices; or
|
For example, we may engage in at-the-market offerings into an
existing trading market in accordance with Rule 415(a)(4) under the Securities Act. We may also sell securities through
a rights offering, forward contracts or similar arrangements.
Except as described in a prospectus supplement or a free writing
prospectus, the securities issued and sold under this prospectus will have no established trading market, other than our common
stock, which is listed on the Nasdaq Global Market. Except as described in a prospectus supplement or a free writing prospectus,
any shares of our common stock sold pursuant to this prospectus will be eligible for listing and trading on the Nasdaq Global Market,
subject to official notice of issuance. Any underwriters to whom securities are sold by us for public offering and sale may make
a market in the securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time
without notice. The securities, other than our common stock, may or may not be listed on a national securities exchange or other
trading market.
We will set forth in a prospectus supplement or free writing
prospectus:
|
·
|
the terms of any underwriting or other agreement that we reach relating to sales under this prospectus;
|
|
·
|
the method of distribution of the securities;
|
|
·
|
the names of any agents, underwriters or dealers, including any managing underwriters, used in the offering of securities;
|
|
·
|
the terms of any direct sales, including the terms of any bidding or auction process, or the terms of any other transactions;
|
|
·
|
the compensation payable to agents, underwriters and dealers, which may be in the form of discounts, concessions or commissions;
|
|
·
|
any activities that may be undertaken by agents, underwriters and dealers to stabilize, maintain or otherwise affect the price
of the securities; and
|
|
·
|
any indemnification and contribution obligations owing to agents, underwriters and dealers.
|
If any underwriters or agents are utilized in the sale of the
securities in respect of which this prospectus is delivered, we will enter into an underwriting agreement or other agreement with
them at the time of sale to them, and we will set forth in the prospectus supplement relating to such offering the names of the
underwriters or agents and the terms of the related agreement with them.
If we sell directly to institutional investors or others, they
may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities. Unless
otherwise indicated in a prospectus supplement or free writing prospectus, if we sell through an agent, such agent will be acting
on a best efforts basis for the period of its appointment. Any agent may be deemed to be an “underwriter” of the securities
as that term is defined in the Securities Act. If a dealer is used in the sale of the securities, we or an underwriter will
sell securities to the dealer, as principal. The dealer may resell the securities to the public at varying prices to be determined
by the dealer at the time of resale.
Remarketing firms, agents, underwriters, dealers and other persons
may be entitled under agreements which they may enter into with us to indemnification by us against certain civil liabilities,
including liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us
in the ordinary course of business.
We may authorize agents, underwriters and dealers to solicit
offers by certain institutional investors to purchase offered securities under contracts providing for payment and delivery on
a future date specified in a prospectus supplement or free writing prospectus. The prospectus supplement or free writing prospectus
will also describe the public offering price for the securities and the commission payable for solicitation of these delayed delivery
contracts. Delayed delivery contracts will contain definite fixed price and quantity terms. The obligations of a purchase under
these delayed delivery contracts will be subject to only two conditions:
|
·
|
that the institution’s purchase of the securities at the time of delivery of the securities is not prohibited under the
law of any jurisdiction to which the institution is subject; and
|
|
·
|
if the securities are also being sold to underwriters acting as principals for their own account, the underwriters shall have
purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have
any responsibility in respect of the validity or performance of delayed delivery contracts.
|
To the extent permitted by and in accordance with Regulation
M under the Securities Exchange Act of 1934, as amended, or the Exchange Act, in connection with an offering an underwriter may
engage in over-allotments, stabilizing transactions, short covering transactions and penalty bids. Over-allotments involve sales
in excess of the offering size, which creates a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the
securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters
to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction
to cover short positions. Those activities may cause the price of the securities to be higher than it would be otherwise. If commenced,
the underwriters may discontinue any of the activities at any time.
To the extent permitted by and in accordance with Regulation
M under the Exchange Act, any underwriters who are qualified market makers on Nasdaq may engage in passive market making transactions
in the securities on Nasdaq during the business day prior to the pricing of an offering, before the commencement of offers or sales
of the securities.
Passive market makers must comply with applicable volume and
price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a
price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market
maker’s bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded.
The specific terms of any lock-up provisions in respect of any
given offering will be described in the applicable prospectus supplement or free writing prospectus.
Under Rule 15c6-1 of the Exchange Act, trades in the secondary
market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. The
applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business
days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to
the second business day before the original issue date for your securities, you will be required, by virtue of the fact that your
securities initially are expected to settle more than two scheduled business days after the trade date for your securities, to
make alternative settlement arrangements to prevent a failed settlement.
In compliance with the guidelines of the Financial Industry
Regulatory Authority, or FINRA, the aggregate maximum discount, commission or agency fees or other items constituting underwriting
compensation to be received by any FINRA member or independent broker-dealer will not exceed 8% of the proceeds from any offering
pursuant to this prospectus and any applicable prospectus supplement.
The underwriters, dealers and agents may engage in transactions
with us, or perform services for us, in the ordinary course of business for which they receive compensation.
No securities may be sold under this prospectus without delivery,
in paper format or in electronic format, or both, of the applicable prospectus supplement or free writing prospectus describing
the method and terms of the offering.
LEGAL MATTERS
The validity of the issuance of the securities offered hereby
will be passed upon for us by Hogan Lovells US LLP. As appropriate, legal counsel representing the underwriters, dealers or agents
will be named in the accompanying prospectus supplement and may opine to certain legal matters.
EXPERTS
Ernst & Young LLP, independent registered public accounting
firm, has audited our consolidated financial statements included in our Annual Report on Form 10—K for the year ended December 31, 2017, as set forth in their report, which contains an explanatory paragraph describing conditions
that raise substantial doubt about the Company’s ability to continue as a going concern as described in Note 1 to the consolidated
financial statements, included therein, and which are incorporated by reference in this prospectus and elsewhere in the registration
statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP’s report, given
on their authority as experts in accounting and auditing.
INCORPORATION BY REFERENCE
The SEC allows us to “incorporate by
reference” information from other documents that we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated
by reference is considered to be part of
this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC
prior to the date of this prospectus.
We incorporate by reference into this prospectus and the registration
statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC:
In addition, all documents that we file with the SEC pursuant
to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial registration statement of which this
prospectus is a part and prior to the effectiveness of such registration statement and all such documents that we file with the
SEC after the date of this prospectus and before the termination of the offering of our securities shall be deemed incorporated
by reference into this prospectus and to be a part of this prospectus from the respective dates of filing such documents.
Any statement contained in a document incorporated by reference
in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement
contained in this prospectus or in any other subsequently filed document that also is or is deemed to be incorporated by reference
in this prospectus modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as
so modified or superseded, to constitute a part of this prospectus.
You may request, orally or in writing, a copy of any or all
of the documents incorporated herein by reference. These documents will be provided to you at no cost, by contacting: Eleven Biotherapeutics, Inc.,
Attn: Chief Financial Officer, 245 First Street, Suite 1800, Cambridge, MA 02142. In addition, copies of any or all of the
documents incorporated herein by reference may be accessed at our website at http://www.elevenbio.com. The information on such
website is not incorporated by reference and is not a part of this prospectus.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy
statements and other information with the SEC. You may read and copy any document we file with the SEC at the SEC’s
public reference room at 100 F Street NE, Room 1580, Washington, D.C. 20549. You may obtain information on the operation of
the SEC’s public reference facilities by calling the SEC at 1-800-SEC-0330. You can request copies of these documents,
upon payment of a duplicating fee, by writing to the SEC at its principal office at 100 F Street NE, Room 1580, Washington,
D.C. 20549-1004. The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy and information
statements, and other information regarding issuers that file electronically with the SEC. Our SEC filings are accessible
through the Internet
at that website. Our reports on Forms 10-K, 10-Q and 8-K, and amendments to those reports, are also
available for download, free of charge, as soon as reasonably practicable after these reports are filed with the SEC, at our
website at http://www.elevenbio.com. The content contained in, or that can be accessed through, our website is not a part of
this prospectus.
$150,000,000
Debt Securities
Common Stock
Preferred Stock
Depositary Shares
Warrants
Units
PROSPECTUS
June 8, 2018
Up to $58,500,000
Shares of Common
Stock
PROSPECTUS SUPPLEMENT
Jefferies
October 30, 2020
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024